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Abstract
Compound promiscuity offers both opportunities and perils for medicinal
chemistry and drug discovery. On the one hand, it is well-established that com-
pounds elicit their therapeutic potential by engaging with multiple proteins, giving
rise to polypharmacology. On the other hand, promiscuous small molecules must
be treated with caution, as their activity towards many targets is often associated
with non-specific binding and assay interference. Thus, an essential step in drug
discovery is to confirm true, beneficial, promiscuity by distinguishing it from
artificial multitarget activity. This thesis aims to elicit molecular mechanisms of
true multitarget activity, to separate them from those of assay interference, and to
identify properties of molecules that can be exploited for polypharmacology.
Hit compounds that originate from biological screening assays display a major
resource for the exploration of promiscuity. Taking potential chemical liabilities of
these compounds into account, 480 substructure patterns of pan-assay interference
compounds (PAINS) have been put forward and are frequently used as structural
alerts in screening efforts. In this thesis, the utility of extensively assayed promis-
cuous compounds as a starting point for the study of pharmacology is explored. In
addition, limitations of PAINS filters are elaborated on the basis of crystallographic
target-PAINS complexes and extensively assayed compounds. Further, series of
analogs containing PAINS are generated to draw structure-activity relationships
between PAINS displaying different activity profiles. To elucidate the structural
context dependence of PAINS activities, structural features that favor correct pre-
dictions of PAINS activities by machine learning models are investigated with
respect to their chemical interpretability. Moreover, analog series of extensively
tested compounds displaying high hit rates are provided, allowing a systematic
analysis of assay interference by circumventing shortcomings of PAINS filters.
Uncertainties associated with screening data are avoided by validating the
promiscuity of small molecules through their presence in experimentally deter-
mined target-ligand complexes. First, ligands are identified that are present in
multiple complexes with distantly related or unrelated targets. These multifamily
ligands are utilized for the generation of template structures that allow the design
of polypharmacology candidates. Finally, chemical properties and binding modes
of multifamily ligands are explored, revealing insight into the mechanisms that
allow molecular recognition of ligands across distinct biological targets.
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1 Introduction
1.1 Drug Discovery
Modern pharmaceutical research originated in the 19th century, when advances
in organic chemistry led to the first synthetically manufactured drugs.1 Based on
by-products of the textile and dye industry, benzene derivatives were among the
first drugs used in analgesia and antipyresis.1,2 Until then, medicines were limited
to substances that were individually isolated from natural products.3 Originally
driven by chemistry, but increasingly influenced by pharmacology and medicine,
the first pharmaceutical companies emerged.1 Today, the pharmaceutical industry
has developed into a billion dollar business and the hunt for new therapeutics has
become a highly complex and long-lasting challenge.4,5 While first discoveries of
bioactive molecules were made on the basis of serendipity, modern drug discovery
focuses on rationalized and thoroughly organized processes covering a wide range
of scientific fields (Figure 1).1,2
The unmet need for therapies for diseases initiates the development of a new
drug.5 First, physiological and pathophysiological pathways associated with a
given clinical condition must be explored. In these pathways, potential molecular
targets must be identified whose manipulation through pharmaceutical agents
can induce a therapeutic effect.5,6 These targets comprise biological structures
that differ in composition and function, including enzymes, genes, receptors,
transporters, ion channels, or RNA.7 However, potential targets must undergo
a validation process and their role in diseases must be clearly defined before
drugs are sought to act against it.8 Identification and validation steps require the
interplay of different disciplines, such as chemical proteomics, genetic screening,
and patient studies.9–11
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Figure 1: Drug discovery process. A schematic representation of the drug discovery
process is shown.
Once suitable experimental assays have been developed, confirmed targets
will be interrogated into screening campaigns. Here, the search for molecules that
modulate target functions and thus elicit a pharmacological effect begins. These
‘hit’ compounds interact with biological macromolecules in different ways, includ-
ing the inhibition of enzymes, activation or deactivation of receptor signaling,
and modification of ion channels.12 For hit-identification, a variety of screening
paradigms exist to investigate biochemical and cellular effects of molecules.5 A
widespread method involves high-throughput screening (HTS), in which large
compound libraries are automatically evaluated for activities against a given tar-
get.13,14 Apart from HTS, other screening methods have been established that,
depending on approach and prior knowledge, utilize DNA encoded compound
repositories, reduced sets of molecules with preferential structure classes, or frag-
ment based libraries.5,14–17 However, hits from initial screening campaigns repre-
sent a heterogeneous mixture of different chemotypes and are often associated
with chemical liabilities that cause artificial assay readouts. Therefore, hit com-
pounds need to be validated and characterized by a second stage of confirmatory
experiments, often referenced as the triaging process.18 Here, truly competitive
behavior of hit candidates is verified by orthogonal testing, dose-response exper-
iments, and X-ray crystallographic target-hit complexes.17–19 Once the integrity
of a hit compound is confirmed, chemical series are prioritized by their synthetic
tractability, drug-likeness, and patentability, to be included in hit-to-lead optimiza-
tion programs.17
Within this process, hit series are structurally modified to provide candidates
with high potency and selectivity, low toxicity, and suitable bioavailability for eval-
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uation in animal studies.5 This multi-objective procedure usually requires many
iterations and is closely linked to the preclinical phase in which pharmacokinetic
and pharmacodynamic parameters as well as toxicology information and initial
dosage profiles are generated in animal models.
The information obtained in these final steps of drug discovery serves for
the design of clinical trials. Divided into three different phases, clinical studies
investigate the therapeutic effect of drug candidates in humans versus placebo
and/or established therapies.20 In phases one and two, the safety, dosage, and
route of administration is investigated in small to medium numbers of volunteers.
Covering a large population of patients in phase three, efficacy and safety of candi-
dates is confirmed by long-term clinical studies.20,21 Ultimately, pharmaceuticals
are granted market access if they meet regulatory requirements.
Drug discovery is a tedious and high-risk process. Research and development
for most therapies available today has taken 12 to 24 years and the cost of this
process rose sharply to an estimated 2.6 billion dollars per drug.22,23 However,
numerous expensive, long-running research projects fail to produce marketable
drugs.24 Often because hit candidates reveal undesired biological and pharma-
cological characteristics that were not properly identified in hit identification
and confirmation steps.19,25 Consequently, it is essential to validate and optimize
early-stage compounds carefully and thus minimize the risk of failure. To achieve
this, knowledge of the molecular basis on which drug candidates elicit desired or
undesired actions in biological and physiological contexts is vital.
The systematic use of chemoinformatic approaches complements resource-
intensive experimental research in this field.26–28 It is a central objective of chemoin-
formatics to explore which structural features influence activity, properties, and
the ability of molecules to interact with target structures.29,30 Therefore, the confir-
mation of compound integrity and activity profiling of drug candidates naturally
benefits from the application of chemoinformatic methods.
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1.1.1 Assay Interference
HTS is considered to be a primary source of new molecular structures in
industrial and academic drug discovery.31,32 Notably, screening data is often made
publicly available and can be explored to study compound activity profiles on a
large scale. For example, the open PubChem BioAssay database provides primary
and confirmatory biological screening data.33 However, the focus on biological
screening hits also bears the risk of pursuing peculiar molecules, which turn out
to be a nuisance in later stages and ultimately condemn research efforts to fail.19
Primary HTS assays are typically single-point experiments that provide qualitative
results. Therefore, lead development candidates are validated in a confirmatory
phase, typically through the collaboration of experts from medicinal chemistry,
biology, and chemoinformatics.17,18
Assay artifacts are multifactorial and hard to detect and rationalize. Often,
however, liable compounds are active against a wide range of targets and display
a promiscuous nature. Moreover, they display certain phenotypes in confirmatory
experiments that raise suspicion. For instance, frequent hitters exhibit an all or
nothing behavior in dose-response experiments and are highly sensitive to assay
conditions. Thus, they are most likely interacting with a component of the assay
system and not with the target protein.5,19 Moreover, analogs derived from assay
artifacts display flat structure-activity relationship (SAR). This indicates that bio-
logical activities are not associated with specific interactions between molecule
residues and target structures, but related to the overall biophysical and chemical
properties of frequent hitters and assay artifacts.19
A variety of computational approaches have been provided to improve the
quality of experimental and virtual screening results. Compound libraries are
initially refined by selecting structures that display favorable physicochemical
properties,34 e.g. as defined by Lipinski’s rule of five for oral drug bioavailability.35
Nevertheless, drug-likeness does not exclude artificial activities and toxicity of
screening compounds.19 For instance, at micro- to submicromolar concentrations,
many drug-like organic molecules undergo colloidal aggregation in assay solu-
tions and incorporate protein targets, thereby inhibiting their function.19,36 Retro
perspective analysis of aggregators led to the introduction of similarity-based com-
putational methods, which assess a screening candidate’s potential to aggregate.37
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The ‘Rapid Elimination Of Swill’ (REOS) procedure was implemented as one of the
first substructural filters that allowed the systematic identification of compound
moieities that might elicit undesired reacitivites or toxicitiy.13 REOS represents a
hybrid method that combines the assessment of physicochemical properties with
filtering out reactive functional groups, e.g. peroxides and isocyanates.13
Expanding the concept of substructure filters, ‘Pan-Assay INterference Com-
poundS’ (PAINS) represent 480 structure classes that are prone to show frequent-
hitting behavior due to their assay interference potential.38 PAINS were experimen-
tally defined by monitoring activity profiles of approximately 100,000 compounds
in six HTS campaigns, utilizing the AlphaScreen technology.38 In this bead-based
assay, a successful interaction between a small molecule and target protein results
in the transfer of a singlet oxygen between donor and acceptor bead that causes
a chemiluminescent signal.39 PAINS filters have found wide acceptance in the
academic and industrial world40 and cover a wide range of structural classes with
different interference mechanisms (Figure 2).
covalent modification metal chelation autofluorescence
Figure 2: Interference mechanisms. Three exemplary PAINS substructures and their pro-
posed mechanism of actions are shown schematically. The PAINS substructure is colored
in red. The Michael-type reaction of a biological nucleophile (Nu) and the exocyclic double
bond of a unsaturated rhodanine (left), copper chelation by hydroxyphenylhydrazones
(middle), and the autofluorescence of aminoacridines (right) are depicted.
For example, unsaturated rhodanines, phenol-sulfonamides, and quinones are
prone to non-specific covalent reactions with biological nucleophiles and protein
residues.25,38,41 These Michael-type reactions also occur for Mannich bases, hy-
droxyphenylhydrazones, and catechols, which can additionally inactivate proteins
through complexation and precipitation of metal ions.38,42,43 Individual mecha-
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nisms of action have been identified including toxoflavins that create reactive
peroxide species,44 curcumin derivatives that interfere by membrane perturba-
tion,45 and aminoacridines, which cause photoinduced interference in fluorometric
assays.46 Many of these structure classes occur in a variety of natural products47 or
approved drugs,48 and some of them have been considered as privileged scaffolds
for drug discovery in the past (Figure 3).49–51
Topotecan
antineoplastic agent
Menadione
nutrional supplement
Zidovudine
antiretroviral agent
Figure 3: PAINS substructures in natural products and approved drugs. Exemplary
natural products and approved drugs containing PAINS motifs are shown. PAINS sub-
structures are colored in red.
Although structure filters such as PAINS draw attention to problematic com-
pound classes and support the triaging process,18,48 they are often viewed con-
troversially. The statistical and experimental foundation of the PAINS concept is
called into question and varying activity profiles of PAINS in different structural
contexts raised awareness of an overestimation of PAINS filters.52–55 Nevertheless,
compound integrity often lies in the eyes of the beholder and successful hit confor-
mation inevitable relies on systematic approaches,18,56–58 especially, when there is
need to distinguish between truly promiscuous compounds and frequent hitters,
as discussed in the following chapter.
1.1.2 Promiscuity and Polypharmacology
From its beginning, drug discovery was guided by the idea of finding the
‘magic bullet’, a drug that elicits its desired therapeutic effect solely based on the
interaction with a specific biological target.59,60 Accordingly, the administration
of a medicine with a broad spectrum of biological activities could lead to un-
6
predictable and eventually adverse reactions. However, this principle had to be
carefully refined when it became apparent that drugs impacting many targets at
the same time better control complex disease systems and are less likely to cause
drug resistance.61,62 The design of new pharmaceutical agents that achieve efficacy
through their ability to influence multiple targets and disease pathways is referred
to as ‘polypharmacology’.61,63–66
Without neglecting the paradigm of single target exclusivity, polypharma-
cology provides additional possibilities for drug discovery.59,64 For example,
polypharmacology accounts for the balance between desired multitarget activity
and harmful promiscuity, i.e. the extent to which promiscuous compounds inter-
act with detrimental off-targets.64,67 In turn, this knowledge can be exploited to
understand and ultimately reduce side effects of drug candidates.68 It has also
been shown that drugs used to treat a particular disease can be repurposed for
other therapeutic applications.69 This implies that promiscuous compounds mod-
ulate additional targets relevant for new applications or that primary targets of
drugs are found in multiple pathophysiological pathways.70 Prime examples of
repurposed drugs include thalidomide, which was initially used in the treatment
of morning sickness and is now applied for leprosis and multiple myeloma,71
and methotrexate, which in addition to cancer has found new applications in
inflammatory diseases such as rheumatoid arthritis.72 Most notably, in the treat-
ment of multifactorial diseases the modulation of a well chosen array of targets
by a promiscuous drug may be preferable to the application of a single target
agent.59,61,63,64 For example, promiscuous kinase inhibitors have proven their clin-
ical utility in oncology by interfering with target networks and associated cellular
signaling pathways.73,74 In addition, multitarget strategies offer a promising ap-
proach for modulation of complex neurotransmitter systems involved in central
nervous system disorders.64,75
The extent of multitarget activities among bioactive compounds and drugs
is still being investigated and it is becoming apparent that expectations of a
widespread drug promiscuity need to be balanced.63,76,77 Although incomplete-
ness and different confidence levels of available data certainly influence these
estimates,78,79 comprehensive analyses of activity profiles from biological screen-
ing assays and the medicinal chemical literature reveal that experimental candi-
dates or drugs are often only active against a small number of targets, or even
7
consistently inactive.79–81 Nevertheless, confined subsets of drugs and highly
promiscuous compounds exist, thereby providing the basis for polypharmacology
approaches.73,81 Given the complex and challenging nature of polypharmacology,
it is important to understand the molecular basis of multitarget activities. To this
end, several computational approaches have been introduced to study promiscuity
on a molecular level. For example, through systematic compound data mining the
SAR of promiscuous compounds was explored and the rational design of mul-
titarget ligands was adressed.81–85 In addition, new targets of compounds were
proposed on the basis of chemical similarities between multitarget ligands,70,86 and
crystallographic data was utilized to study binding sites and functional similarities
of targets that bind promiscuous ligands.87,88
Importantly, compound promiscuity as the basis for polypharmacology does
not include nonspecific binding events of frequent hitters due to assay interference
or other compound liabilities.64 Therefore, it is crucial to validate true multitar-
get activity before studying promiscuity. In the present work, chemoinformatic
approaches are discussed that evaluate multitarget binding events on the basis
of molecular similarity and molecular interactions of promiscuous compounds.
This SAR analysis is based on biological screening data and crystallographic
target-ligand complexes.
1.2 Structure-Actvity Relationship
SAR analysis aims to establish the relationship between chemical structures
and biological responses of active compounds. Traditionally these relationships are
drawn for individual series of structurally homologous compounds that are tested
against small sets of related targets and off-targets, respectively.89 The emergence
of larger data sets through efficient biological screening methods and publicly
accessible experimental data enabled computational methods for a large-scale
SAR exploration.
In general, these methods can be classified as descriptive and predictive. Descrip-
tive methods identify SAR determinants by a retro perspective deconvolution and
visualization of available SAR information. On the other hand, predictive meth-
ods, such as the quantitative SAR (QSAR), attempt to predict biological activity
of novel, untested compounds by establishing a correlation between biological
8
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Figure 4: SAR characteristics. A series of compounds that displays continuous SAR
character is shown (left to right). On the vertical axis, compound pairs that display a
discontinuous SAR are given. Below each molecule its biological activity (pKi) against
tyrosine-protein kinase JAK1 and the promiscuity degree (PD) are given. One activity-
and promiscuity cliff is highlighted (green and orange arrow, respectively). Substitution
sites are traced in blue.
activity and structural or chemical properties.90 Common to QSAR models is that
they conceptually rely on the so-called ‘similarity property principle’.91 It states
that structurally related molecules should have similar properties. Accordingly,
small structural changes should only result in minor potency variations and a con-
tinuous SAR (Figure 4). However, exceptions for this rule are frequently observed
and represented by structurally homologous compounds that elicit heterogeneous
biological activity, thereby displaying a discontinuous SAR (Figure 4). The most
extreme form of SAR discontinuity are activity cliffs.92,93 They are formed by
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two structurally similar compounds having a large potency difference. Activity
cliffs represent a particular rich source of SAR information by identifying small
structural modifications having a major influence on compound potency (Figure
4).93
However, as previously discussed, biological activity is not the only deter-
minant of a drug’s therapeutic efficacy and utility for drug discovery efforts. To
expand the scope of SAR analysis, additional compound properties are inves-
tigated. These can include physicochemical features or the promiscuity degree
(PD), i.e. the number of targets a compound is active against. It has been shown
that promiscuity of analogous compounds, similar to biological activity, is not
invariably linear, and small structural modifications can lead to the formation
of promiscuity cliffs between structurally related compounds (Figure 4).94 In the
light of apparent multitarget activities, descriptive SAR analysis provides a useful
method to explore the molecular basis of assay interference and identify SAR
determinants of undesired chemical reactivity.
1.2.1 Molecular Similarity
Molecular similarity refers to the concept of clustering compounds on the basis
of structural features, biological effects or physicochemical properties.95,96 This
principle finds application in a variety of chemoinformatic methods that either
aim to predict compound properties, search and extract large databases for similar
molecules, or design new entities with desired descriptors.95
However, the medicinal chemist’s perception of similarity is usually guided
by intuition, knowledge, and individual experience.18,96 There is often little agree-
ment between experts compound classification based on desired or undesired
structural features and results vary depending on the context in which structures
are presented. In addition, similarity comparison is driven by the focus on local
patterns that are responsible for a distinct biological response such as activity or
interference.18,57,58,97 On the other hand, chemoinformatic approaches towards a
systematic similarity assessment offer the possibility to circumvent this subjective
nature.96 The computational evaluation of molecular similarities is based on two
aspects. First, the representation of molecules covering relevant structural and
functional features. Second, a method that extracts information encoded in such
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representations and determines similarity between molecules. In general, simi-
larity can be evaluated in a quantitative or qualitative manner and the results of
similarity assessments depend on applied methodology and structural diversity
of investigated compounds.96 Therefore, different molecular representations and
methods to determine similarity will be discussed in the following.
1.2.2 Molecular Representations
Molecular representations encode structural features and/or properties of a
molecule. They vary in complexity and included chemical information depending
on the desired application. Molecular representations can be subdivided into one-,
two-, and three-dimensional ones (1D, 2D, and 3D, respectively).96,98
1D representations include the molecular formula, as well as the simplified
molecular input line entry specification (SMILES).99 Based on predefined rules,
SMILES are linear notations that represent molecular structures by taking into
account atom types, branching, stereochemistry, and aromaticity. Notably, PAINS
substructures are annotated as SMILES arbitrary target specification (SMARTS),
an extension of SMILES that introduces atom and bond labels containing logical
operators (Figure 5). SMARTS are typically used for substructure searches in
compound databases.38,100
SMILES:
c1cc(O)c(O)cc1C=C2C(=O)C(=Cc3cc(O)c(O)cc3)CC2         
PAINS SMARTS:
[#6]=!@[#6](-[!#1])-@[#6](=!@[!#6&!#1])-@[#6](=!@[#6])-[!#1]
Figure 5: PAINS substructure. A divinyl ketone that is classified as PAINS is shown. In
the molecular graph representation of the compound, atoms and bonds that are part of
the PAINS substructure are colored in red. Corresponding characters in the SMILES are
also colored in red and the SMARTS string of the PAINS substructure is provided.
Molecular graphs are 2D representations of small molecules that provide an
intuitive model of molecular topology and structure. In these graphs, nodes and
edges correspond to atoms and bonds, respectively (Figure 6). To represent the
steric and electronic properties of a molecule, 3D representations additionally take
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into account the spatial arrangement of atoms and bonds. These 3D representations
are typically used to determine a molecule’s conformation, surface, or volume.96
To provide a computer-interpretable form of 2D or 3D representations, atom
coordinates, bond orders, charges, and hybridization states can be encoded into
connectivity tables, such as in MOL or PDB file types.101,102
On the basis of the aforementioned structure-based molecular representations,
molecules can additionally be described in terms of numerical values. These
molecular descriptors are mathematical models that capture a variety of chemical
properties of compounds.98,103,104 1D descriptors are calculated on the basis of
linear notations and do not consider atom connectivity information. These simple
descriptors include for example atom counts and molecular weight. Descriptors
that require the molecular topology and structure are called 2D descriptors. Such
2D descriptors are approximated physicochemical properties such as SlogP105 or
topological indices like the topological polar surface area (TPSA).106 Finally, 3D
descriptors, such as the solvent accessible surface area, are calculated on the basis
of a compounds distinct 3D conformation.
Fingerprints (FPs) are a subset of molecular descriptors that are utilized in
chemoinformatics to represent a molecule as a numerical vector (Figure 6).108 In
binary fingerprints, a position in the bit vector accounts for the absence or presence
of a specific chemical feature. The presence of a feature will set the corresponding
bit to 1, while its absence will set it to 0. In non-binary versions of fingerprints, each
position numerically accounts for the frequency of occurrence of the underlying
feature. Based on the molecular representation they originate from (i.e. 2D graph
or 3D conformation), fingerprints are typically classified as 2D or 3D. In addition,
fingerprints vary in the chemical features they use. Substructure fingerprints
utilize dictionaries with predefined substructures and create fingerprints of fixed
length. One prime example is the molecular ACCess system (MACCS) consisting
of a set of 166 structural patterns.109
In contrast, combinatorial fingerprints are of variable length and molecule-
specific as they do not use predefined substructures. For example, extended-
connectivity fingerprints (ECFPs) encode all possible subgraphs of a given molecule
up to a specific bond diameter.110 For the comparison of molecules represented as
fingerprints suitable similarity metrics, including a varity of coefficienct and dis-
tance functions, are used.96 However, these whole-molecule similarity assessments
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are often difficult to reconcile with medicinal chemistry approaches. The outcome
of a similarity assessment often changes with the used fingerprint. Moreover, no
generally applicable thresholds for similarity coefficients that indicate structural
or activity similarity exist. Hence, the use of a metric represents a quantitative
assessment of molecular similarity in which compounds are ranked by a numeri-
layer atoms
1 C
2 N C
3 C O C
descriptors
molecular weight [g/mol]: 435.9
number of atoms: 47
SlogP: 2.52
TPSA [Å]: 88.2
3D conformation
substructure FP combinatorial FP
2D graph
Figure 6: Molecular representations. Rivaroxaban and schematic representations of fin-
gerprints, descriptors, and a 3D conformation, are shown. For the substructure fingerprint
(FP) the bit string is represented as a set of cells. Orange cells denote chemical patterns
present in the molecule. White cells represent absent patterns. For the combinatorial FP,
concentric layers with a maximum radius of 2 around a exemplary root atom are shown.
For each layer, the type of additional atoms is reported. Finally, molecular descriptor val-
ues and the 3D binding conformation of rivaroxaban against factor Xa are given (PDB-ID:
2W26).107
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cal value. In contrast, the application of a structure-based similarity assessment
that is based on predefined rules provides a qualitative result, i.e. whether two
compounds are similar to each other or not.89,96
1.2.3 Matched Molecular Pairs
The concept of matched molecular pairs (MMPs) allows a structure-based
comparison of molecular representations that circumvents the subjective nature
of similarity thresholds and provides a chemically intuitive view on molecular
similarity. MMPs are defined by a pair of molecules that only differs by a structural
modification at a single site.111 Consequently, compounds that display a MMP
relationship can be interconverted into one another by the exchange of a substruc-
ture, often termed chemical transformation (Figure 7).112 MMP-based analyses
have found large acceptance and are used for a wide range of chemoinformatic
applications, such as SAR matrices, and the exploration of activity cliffs.93,113,114
One of the first methods to calculate MMPs utilized the maximum common sub-
structure (MCS) of a compound pair.115 In this method, the largest substructure
shared between a pair of molecules is determined and identified as the shared
core. The remaining part of the compounds represents the chemical transforma-
tion. However, MCS-based MMP generation is computationally not efficient as it
requires the generation of MCS for all possible compound pairs in a data set.115,116
Alternatively, shared substructures between compound pairs can be identified
using fragmentation-based algorithms. In a simplified manner, these algorithms
can be regarded as a two-step process. In the first step, a compound library is sub-
jected to a rule-based fragmentation procedure. The second stage results in MMP
identification by indexing and subsequent comparison of generated fragments.
In comparison to MCS-based approaches, fragmentation-based algorithms can
be applied to large data sets and are computationally more efficient since each
molecule is processed only once.
A widely used fragmentation-based algorithm was introduced by Hussain
and Rea.117 In this fragmentation process, each exocyclic single bond between
two non-hydrogen atoms is cleaved. These so-called ’single cuts’ result in two
fragments. The larger fragment of a compound is termed ‘key’ and the remaining
smaller substructure as ‘value’. Fragmentation can also occur at two or three
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bonds at the same time, thereby generating ’double-’ or ’triple-cut’ fragments,
respectively. Generated fragments are stored as key-value pairs in an index table. A
key entry (i.e. the shared molecular core) that refers to two values (i.e. the different
substituents) represents an MMP.
However, keys and values are often not chemically intuitive. Transformation
size-restricted MMPs have been introduced to ensure that key fragments are larger
than values. This confines MMPs to structurally analogous compounds that differ
by interpretable substitutions, such as functional groups or single ring systems.114
Additionally, fragmentation of molecules based on the well-known retrosynthetic
combinatorial analysis procedure (RECAP)118 allows for synthetically accessible
transformations between MMPs, often referred to as RECAP-MMPs (RMMPs)
(Figure 7).119
RECAP-matched molecular pair (RMMP)
RECAP-matching molecular series (RMMS)
analog series (AS)
Figure 7: Matched molecular pair, matching molecular series, and analog series (AS).
Shown are analogs of unsaturated rhodanines forming a RECAP-matched molecular
pair (top), a RECAP-matching molecular series (middle), and an analog series (bottom).
Exchanged substructures are highlighted in blue and orange, respectively.
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Matching molecular series (MMS) represent an extension of the MMP con-
cept.120 MMSs are sets of three or more molecules that share a common substruc-
ture, i.e. a key fragment that has more than two value fragments. All compounds
in the MMS display a pairwise MMP relationship and thus represent a series of
analogs with structural modifications at a single site. MMSs that are derived from
RECAP transformations are termed RECAP-MMSs (RMMSs) (Figure 7). Computa-
tional SAR exploration based on series, such as RMMSs, reflect the series-centric
efforts that dominate medicinal chemistry programs.
To comprehensively cover the analog space of a given compound data set, the
concept of analog series (AS) has been introduced.121 In this approach, RMMPs are
systematically organized in global networks where nodes represent compounds
and edges a pairwise RMMP-relationship. Each disjoint cluster represents a dis-
tinct AS. ASs may combine RMMSs with overlapping compounds. In contrast
to RMMSs, where a compound can be part of multiple RMMSs, compounds are
exclusively assigned to one specific AS. Thus, ASs cover all chemically explored
substitution sites and available substitution patterns of analogous compounds
(Figure 7).121
1.2.4 Scaffolds
From a medicinal chemist’s point of view, a scaffold represents the core struc-
ture of bioactive molecules to which structural modifications are synthetically
introduced to exchange functional groups. Typically, this iterative process results
in a series of analogous compounds, in which substitutions of the core structure are
presented in R-group tables.114 In this case, the definition of a scaffold relies on the
structural context of the series and the subjective perception of a chemist. However,
chemoinformatic approaches aim to compare the SAR of different series, system-
atically replace core structures, or structurally organize large screening libraries.
Hence, computational methods require a consistent definition of scaffolds.114
A widely applied molecular graph based definition was provided by Bemis
and Murcko (BM).122 This approach follows a molecular hierarchy by dividing a
compound into ring systems, chemical linker fragments, and R-groups. A scaffold
is obtained by removal of all R-groups while retaining ring systems and linker
elements connecting two or more rings. From a chemical perspective, this method
16
analog series
BM scaffolds
ASB
Figure 8: Scaffolds. For an exemplary AS, corresponding BM and ASB scaffolds are shown.
Exchanged substructures are colored according to the substitution site of the ASB scaffold
(R1, orange and R2, blue).
contains intrinsic limitations. By definition, the addition of a ring to a BM scaffold
yields a new scaffold, although experimental analog generation often introduces
additional rings to core structures as R-groups. In addition, BM scaffolds are not
generated considering chemical reaction information.122
As an alternative to the compound based definition of BM scaffolds, AS-based
(ASB) scaffolds were introduced that are derived from ASs containing single
as well as multiple substitution sites (Figure 8).123,124 The generation of an ASB
scaffold can be rationalized by considering RMMS (vide supra). By definition, a
RMMS represents the most simple form of an AS that contains only analogs with
a single substitution site. Consequently, ASs covering multiple substitution sites
must consist of more than one overlapping RMMS. Thus, two overlapping RMMSs
must share at least one analog with structural modifications at two distinct sites,
17
therefore participating in two RMMPs. The overlapping part of two RMMS-cores
(i.e. the RECAP-MMP cores of two RMMSs) yields the ASB scaffold of the AS. In
contrast to BM scaffolds, ASB scaffolds include retrosynthethic information and
are not restricted by a predefined molecular hierarchy. In addition, the use of a BM
scaffold determines the composition of a series and may possibly limit the chemical
information it contains. ASB scaffolds, on the other hand, are derived from existing
ASs. Thus, ASB scaffolds ensure that all conserved structural elements of ASs are
covered (Figure 8) and, according to the properties of corresponding analogs, ASBs
can be utilized as templates for the design of focused compound libraries.124
1.3 Three-Dimensional Target Structures
The completion of the human genome project led to the identification of disease-
associated anomalies at the gene level and to complementary proteomic research
characterizing (patho)physiological mechanisms of complex diseases. This has
enabled the discovery of numerous potential drug targets whose structure and
function is investigated at the molecular level of 3D target structures.125,126 Typi-
cally, 3D structures of human and pathogenic proteins are determined by X-ray
crystallography, NMR spectroscopy, and cryo-electron microscopy.127–129 Within
the last years, an extensive knowledge base of structural data has been obtained
that allows molecular details of a drug-target interaction to be investigated and
exploited for the design of optimized compounds. This process is often referred to
as structure-based drug design, and covers a variety of computer aided methods,
including molecular docking and homology modeling.27,130
In the context of assay interference and multitarget activities, target-ligand
complexes provide firm evidence for true binding events. Hence, they can be
utilized to circumvent uncertainties associated with biological screening data to
explore the molecular basis of promiscuity. Although pharmaceutical companies
keep many experimental structures unpublished, a significant amount of structures
was made publicly available.
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1.3.1 The Protein Data Bank
Since its launch in 1971, the Protein Data Bank (PDB) has grown to the largest
source of publicly available experimental complex structures. Starting with only
seven protein structures, the PDB archive has experienced a nearly exponential
growth over the years and by now contains more than 147,633 entries (accessed on
January, 16 2019).131 Those include 132,376 X-ray, 12,494 NMR, and 2,763 electron
microscopy structures. Proteins represent the major type of molecules in the PDB
compared to nucleic acids, and protein nucleic acid complex structures with 2,2%
and 5,0% of the total number of entries, respectively. The PDB presents a global
view of structural biology that goes beyond the simple provision of structural
data, i.e. atomic coordinates. For example, sequence and 3D structure similarity
information is made available for deposited structures as well as corresponding
metabolic pathways and gene information. In addition, co-crystal structures of
bioactive ligands are mapped in DrugBank and PDBbind to provide potency
annotations and further information about ligands.132,133 This also includes inter-
active tools to visualize whole protein structures, target ligand interactions, and
binding sites.134 Although experimentally determined 3D structures are of great
value for the binding mode analysis and optimization of drug candidates, they
are associated with intrinsic limitations. First, X-ray complexes are not equally
accessible for all target structures. For example, cell membrane-associated pro-
teins, such as receptors or ion channels, can adopt different conformations and
are hard to crystallize in their natural environment of the lipid bilayer.129,135
This results in an over-representation of cytosolic and secreted proteins in the
PDB.131 Secondly, crystal structure coordinates provide a misleading static view
of molecular interactions and protein-ligand binding events. In reality, it must be
assumed that a macromolecular complex is an ensemble of several conformations
that continuously transform into each other. Moreover, it is the underlying ther-
modynamic process includes desolvation, long-range interactions, and entropic
effects involving protein, ligand, and solvent.136–138 Therefore, a crystal structure
provides a time-average view of the protein-ligand complex under experimen-
tal crystallization conditions. However, it is assumed that molecular recognition
in biological systems relies on the existence of specific short-range interactions
and a high degree of shape complementarity between protein and ligand.136,139
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Thus, experimentally determined complexes do not only provide evidence of true
binding events, but can also be used to explore molecular mechanisms that allow
promiscuous compounds to bind distinct targets.
1.3.2 Target-Ligand Interactions
While molecular modeling techniques, such as quantum mechanics and molec-
ular dynamics, investigate short-range interactions in a 3D manner, chemoinfor-
matic approaches typically transform experimentally determined complexes into
2D or 1D representations.140 Hence, the combination of both approaches allows
for efficient analysis of a large array of 3D information. A prime example of this
interplay represents the analysis of structural similar crystallographic ligands that
display large differences in potency against a specific target. This study provided
a structural rationale for activity cliffs.141,142 Various chemoinformatic approaches
have been introduced that can process large amounts of protein-ligand complexes.
For example, schematic 2D diagrams of protein-ligand interactions are used to
facilitate an initial assessment of structural binding site information and provide a
summary of interaction distances and energies (Figure 9).143
Further simplifying 3D complexes, protein-ligand interaction fingerprints
(PLIFS) encode the absence or presence of specific interactions between ligand
atoms and protein residues, thus providing a 1D structural interaction profile of a
ligand. PLIFs typically find application in the post-processing of docking results
and the analysis of large data sets.140,144,145 For example, they have been utilized
for the assessment of ligand binding similarities across related target proteins.146
Depending on the underlying method, interactions are identified by geometrical
criteria, i.e. distance and angle between ligand and protein atoms (Figure 9).136,143
Additionally, favorable interactions are often prioritized based on their interaction
energies, which are typically derived from empirical- or knowledge-based scoring
functions.147,148 Recent advances in the implementation of molecular modeling
applications149 in modular pipelining tools150 provide the possibility to rapidly
convert large amounts of 3D structure data into easily interpretable 2D and 1D
information. If an appropriate number of complexes of a given ligand with dis-
tantly related or unrelated targets is available, a structure-based investigation of
promiscuity at the molecular level of detail is possible.
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3D binding site 2D interaction diagram
Gly219
Phe174
Tyr99
Trp215
ligand atom receptor atom interaction type distance [Å]
O19 N-Gly219 hydrogen bond(acceptor) 2.97
N21 O-Gly219 hydrogen bond(donor) 3.26
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21
21
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Figure 9: Binding mode analysis. The X-ray structure of human factor Xa in complex
with rivaroxaban (green color) is shown (top, left). In the 3D depiction of the binding
site, the protein backbone and protein residues are colored grey and blue, respectively.
A ligand-target interaction diagram of the complex taken from the PDB is depicted (top,
right; PDB-ID: 2W26).107 Short-range interactions of rivaroxaban and human factor Xa are
illustrated as dashed lines in the 3D and 2D depiction, respectively. For these interactions,
involved atoms of ligand and receptor, interaction types, and distances are provided in a
table format.
1.4 Outline of the Thesis
This thesis focuses first on the analysis of assay interference and promiscuity
based on extensively tested compounds originating from biological screening
assays. In chapter 2, a subset of highly promiscuous screening compounds is
submitted to publicly available PAINS filters and the chemical integrity of fil-
tered compounds is inspected. Shortcomings of structural alerts are elaborated
on promiscuous compounds associated with chemical liabilities. Additionally,
candidates for polypharmacology with no apparent liabilities are provided. In
chapter 3, crystallographic complexes of PAINS and biological target structures
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are explored. On the basis of structurally confirmed binding events different cat-
egories of PAINS-containing ligands are distinguished. Further, the structural
context dependency of PAINS activities is rationalized on a structural level.
The following chapters focus on the SAR analysis of PAINS. In chapter 4, ASs
containing PAINS are generated. Activity profiles of compounds with differently
embedded PAINS substructures are studied and structural modifications that
affect PAINS activities are elaborated. In chapter 5, ECFP4 structural features that
favor the correct classification between promiscuous and consistently inactive
PAINS by machine learning models are identified. Furthermore, these features
are evaluated with respect to their role in the structural context dependence and
chemical interpretability of PAINS activities. In chapter 6, a data driven statistical
analysis of hit rates of extensively assayed compounds is carried out. Without
prior filtering steps, MMSs containing compounds with high assay promiscuity are
generated and provide a basis for the systematic assessment of assay interference,
taking structural context information into account.
In the final chapters, the structure-based approach is revisited to explore com-
pound promiscuity. In chapter 7, multitarget ligands and multifamily ligands are
identified on the basis of structurally confirmed binding events. For these promis-
cuous ligands, additional analogs and target annotations are systematically de-
rived from medicinal chemistry literature and ASB scaffolds are isolated that serve
as templates for polypharmacological ligand design. In chapter 8, promiscuous
ligands are characterized based on molecular properties. Moreover, binding con-
formations and interaction hotspots of multifamily ligands are comprehensively
analyzed to rationalize their promiscuous binding behavior. The final chapter
summarizes the main points of this work and serves as a conclusion of the thesis.
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2 Highly Promiscuous Small
Molecules from Biological Screening
Assays Include Many Pan-Assay
Interference Compounds but Also
Candidates for Polypharmacology
Introduction
In the context of polypharmacology, the promiscuity of small molecules must
be considered from different perspectives. On the one hand, it is well-known that
multitarget-dependent pharmacological effects are mediated by promiscuous com-
pounds interacting with multiple distantly or unrelated targets. On the other hand,
the promiscuous behavior of small molecules is often associated with non-specific
binding events or assay artifacts caused by undesired chemical and biological
reactions.
In this chapter, the application of public structural filters is combined with the
knowledge-based assessment of chemical liabilities of extensively tested screening
compounds. Aggregators and PAINS found in highly promiscuous compounds are
identified and potential shortcomings of currently available structural alerts are
highlighted. Compound integrity is verified by visual inspection and consideration
of high-confidence activity data from medicinal chemistry literature to provide
candidate compounds for polypharmacology.
23
This study provides a starting point for the future improvement of detec-
tion methods and the exploration of molecular details of desired and undesired
promiscuity.
My main contribution to this work was the visual inspection and knowledge-
based identification of chemical liabiltities in highly promiscuous screening com-
pounds.
Reprinted with permission from ’E. Gilberg, S. Jasial, D. Stumpfe, D. Dimova,
J. Bajorath. Highly Promiscuous Small Molecules from Biological Screening As-
says Include Many Pan-Assay Interference Compounds but Also Candidates for
Polypharmacology. Journal of Medicinal Chemistry 2016, 59, 10285–10290.’ Copyright
2016 American Chemical Society
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Highly Promiscuous Small Molecules from Biological Screening
Assays Include Many Pan-Assay Interference Compounds but Also
Candidates for Polypharmacology
Erik Gilberg, Swarit Jasial, Dagmar Stumpfe, Dilyana Dimova, and Jürgen Bajorath*
Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische
Friedrich-Wilhelms-Universitaẗ, Dahlmannstrasse 2, D-53113 Bonn, Germany
ABSTRACT: In PubChem screening assays, 466 highly
promiscuous compounds were identified that were examined
for known pan-assay interference compounds (PAINS) and
aggregators using publicly available filters. These filters
detected 210 PAINS and 67 aggregators. Compounds passing
the filters included additional PAINS that were not detected,
mostly due to tautomerism, and a variety of other potentially
reactive compounds currently not encoded as PAINS. For a
subset of compounds passing the filters, there was no evidence
of potential artifacts. These compounds are considered
candidates for further exploring multitarget activities and the
molecular basis of polypharmacology.
■ INTRODUCTION
Multitarget activities of small molecules can be considered from
different viewpoints. For example, polypharmacology is an
emerging theme in pharmaceutical research and results from
compounds or drugs that act on multiple physiological targets
and elicit multitarget-dependent pharmacological effects.1−3 In
the context of polypharmacology, compound promiscuity is
defined as the ability of small molecules to specifically interact
with multiple targets.4,5 Such instances of “good” promiscuity
must be distinguished from nonspecific interactions or other
undesirable effects, leading to artificial activity readouts in
biological assays (“bad” promiscuity).6−9 These include
aggregating compounds leading to nonspecific inhibition6,7
and other compound classes known to produce assay artifacts
referred to as pan-assay interference compounds (PAINS).8,9
Exemplary PAINS are small molecules that are reactive under
assay conditions and produce false-positive signals, which
presents a major problem for medicinal chemistry.9 So far,
more than 400 compound classes are regarded as PAINS
including, among others, rhodanines, curcumines, or qui-
nones.8,9 However, it is often complicated to unambiguously
detect PAINS.10 To these ends, implementations of PAINS
filters have been made publicly available in software tools11,12
or databases.13,14 In addition, a public filter for aggregators has
also been generated.15
In this study, we have determined the most promiscuous
compounds from publicly available screening assays.16 For the
majority of these compounds, available activity data met high-
confidence criteria. These promiscuous compounds were
searched for PAINS and aggregators, which identified a large
number of liable molecules. In some instances, PAINS motifs
were not detected by standard filters and other compounds
passing the filters also included potentially reactive molecules
or chelators not encoded as PAINS. For some highly
promiscuous compounds, structural analogues with varying
target annotations were identified. In addition, for a subset of
promiscuous compounds passing the filters, no obvious
liabilities were found. Thus, these compounds might be
relevant for the study of polypharmacology.
■ RESULTS
Identification of Highly Promiscuous Compounds.
From PubChem,16 compounds were extracted that were
extensively tested in primary and confirmatory assays. Primary
assays represent initial biological screening data and typically
report compound activity as a percentage of inhibition using a
single compound concentration. In confirmatory assays, activity
measurements are performed at varying compound concen-
trations, yielding activity values derived from titration curves.
We searched for PubChem compounds that were tested in
more than 300 primary plus more than 50 confirmatory assays
and identified 123,844 qualifying compounds. For each of these
compounds, the promiscuity degree (PD; see Methods and
Materials) was calculated separately for primary and con-
firmatory assays and compounds were ranked for each assay
category in the order of decreasing PD values. Then the overlap
among the top 1000 compounds in both rankings was
determined, resulting in 466 highly promiscuous compounds
(Figure 1).
These compounds were tested in a total of 373−775 assays
and reported to be active against 36−128 unique targets on the
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basis of PubChem assay records. They represented the most
promiscuous compounds we have been able to identify. One
might anticipate that compounds having such high degrees of
promiscuity are particularly prone to assay artifacts. Therefore,
these compounds were initially screened for PAINS and
aggregators.
PAINS and Aggregator Screening. Different public filters
detected 210 of 466 highly promiscuous PubChem compounds
as PAINS (45.1%). In addition, 67 compounds were found to
be known aggregators (14.4%). The remaining 189 compounds
(40.6%) (Figure 1) were further analyzed.
Undetected PAINS. Visual inspection of the 189
compounds passing all filters identified 22 compounds that
were PAINS or tautomers of PAINS but not detected by filters.
These compounds included a toxoflavin, two quinones, and 19
tautomers of hydroxyphenylhydrazones (Figure 2). These
findings pointed at a problematic issue with PAINS
implementations that do not take tautomerism into account.
Compounds with Other Potential Liabilities. Com-
pounds passing the filters also included other reactive
compounds, fluorescent molecules, or chelators that were not
encoded as PAINS. For example, we identified 17 compounds
for which data from the medicinal chemistry literature available
in ChEMBL13 identified additional targets. Figure 3 shows
these compounds. They were active against a diverse array of
targets from a variety of families, without a notable tendency of
preferential activity against individual targets or families.
Compounds in Figure 3 include examples of reactive
compounds. For example, the photosensitive potential of
biothionol 1 has been noted,19 which led to its withdrawal
from the market by the FDA.20 Moreover, compounds 2 and 6
might undergo ring-opening reactions at sulfur or selenium
atoms.21 In addition, the sesquiterpenlactone helenalin22 11
and the maleimide 12 act as Michael acceptors23 and
compound 16 was reported to react with thiols.24 Furthermore,
compound 4 contains a reactive nitro group and 10 is capable
of chelating metal ions.25 To what extent these properties give
rise to systematic assay artifacts remains to be determined.
Clearly, it is often difficult to draw a line between known
PAINS and compounds containing other potentially reactive
moieties. Figure 3 also contains other examples. Compounds
14 and 15, for example, have no apparent liabilities, and
compound 3 is a known promiscuous kinase inhibitor26 for
which 63 analogues with annotations for 16 kinases are
available in ChEMBL. Compound 3 is a good example of a
polypharmacological compound.
Promiscuous Compounds with Analogues. For 31 of
the compounds passing the filters, 1−63 structural analogues
with available high-confidence activity data were identified in
ChEMBL. These analogues belonged to a total of 28 analogue
series, 26 of which were annotated with multiple (2−47) targets
reported in the medicinal chemistry literature.
High-Confidence Activity Data. For all 466 highly
promiscuous compounds, a search for high-confidence activity
data was carried out in ChEMBL. The availability of high-
confidence activity data was thought to lend credence to
multitarget activities observed in screening assays. ChEMBL
contained assay data incorporated from PubChem that met at
least in part high-confidence activity data criteria (see Methods
Figure 1. Highly promiscuous compounds and their analysis. The
flowchart summarizes the steps involved in the identification and
analysis of highly promiscuous compounds from PubChem.
Figure 2. Undetected PAINS. Shown are (a) a toxoflavin and two
quinones and (b) representative examples of tautomers of
hydroxyphenylhydrazones that were not detected by public PAINS
filters. Known PAINS substructures are colored red.
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and Materials) for 206 of the 277 compounds detected as
PAINS or aggregators and for 114 of the 167 compounds
passing the filters. Thus, high-confidence activity data was
available for most highly promiscuous compounds regardless of
their structural characteristics.
Figure 4 shows the distribution of PD values for all PAINS
and aggregators (with a median PD of 56) in comparison to
promiscuous compounds passing the filters (median PD of 52).
The distributions were rather similar and PD values were only
slightly larger for known PAINS and aggregators than for other
promiscuous compounds. Hence, there were also no significant
differences in apparent promiscuity levels between these
compound subsets. Clearly, from the magnitude of PD values
alone, no conclusions about artificial or true compound
activities can be drawn.
Candidates for Polypharmacology. The 167 highly
promiscuous compounds passing the filters were subjected to
visual inspection in light of the PAINS results and other
potential activities, as described above, and a subset of 30
compounds was identified that did not display obvious
chemical liabilities. Figure 5 shows exemplary compounds.
These compounds are thought to represent interesting
candidates for the study of polypharmacology. It is noted that
compound 21 might decompose over time into different
products,27 an example of a potential activity that may or may
not affect biological activities or assay interference.
Figure 3. Highly promiscuous compounds with additional targets. Shown are 17 compounds from PubChem assays for which high-confidence
activity data from the medicinal chemistry literature in ChEMBL identified additional targets. For each compound, target annotations are reported
(bottom). “x + y” means that “x” unique targets originated from PubChem assay data and “y” additional targets from separate activity records in
ChEMBL. Compounds for which structural analogues with high-confidence activity data were found in ChEMBL are shown in bold. Compounds
with potential liabilities not detected by filtering, as discussed in the text, are colored blue.
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We also emphasize that putative reactivities do not preclude
the evaluation of candidate compounds for polypharmacology.
In fact, putative liabilities often suggest experimentally testable
hypotheses. For example, if a compound is thought to elicit
“bad” promiscuity through chelator properties, examples are
shown in blue in Figure 3, derivatives with substitutions of
chelating atoms can be assayed, and it can be determined
whether or not these derivatives become inactive. If not, the
compound becomes even more interesting for the assessment
of multitarget activities. Hence, the subset of candidates for the
study of polypharmacology might well be further extended
beyond the 30 compounds we have prioritized.
■ DISCUSSION AND CONCLUSIONS
In this work, compounds displaying high degrees of
promiscuity in screening assays were identified and analyzed.
We deliberately focused the analysis on the pinnacle of
currently detectable promiscuity, taking into consideration
that high degrees of promiscuity might often result from
artifacts in screening assays. The set of 466 compounds upon
which our analysis was based were the most promiscuous ones
we have been able to identify. As anticipated, the majority of
these compounds were detected as PAINS or aggregators and
represented exemplary cases of “bad” promiscuity. In addition,
false-negative PAINS were identified that remained undetected
by public filters, mostly due to tautomerism, as well as other
compounds potentially causing assay artifacts that were not
encoded as PAINS. These problematic issues are expected to
apply to many more classes of PAINS and other potentially
reactive molecules than covered by our set of highly
promiscuous compounds. Public PAINS filters and other
detection methods are of critical importance for the medicinal
chemistry community but they are currently not sufficiently
developed to be fully reliable, as indicated by different types of
false-negatives detected in our analysis. High-confidence
activity data were available for many compounds detected as
PAINS as well as others passing the filters. Thus, the availability
of high-confidence activity data is considered a necessary but
not sufficient condition for compound integrity.
Figure 4. Class-specific promiscuity degrees. The PD value
distribution of detected PAINS and aggregators is compared to the
distribution of other promiscuous compounds passing the filters for
which high-confidence data or analogues were available. Boxplots
report the smallest value (bottom line), first quartile (lower boundary
of the box), median value (thick line), third quartile (upper boundary
of the box), and largest value (top line).
Figure 5. Candidates for polypharmacology. Shown are exemplary promiscuous compounds that passed the filters and did not display obvious
chemical liabilities. For each compound, the PD is reported on the basis of target annotations from PubChem (bottom).
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.6b01314
J. Med. Chem. 2016, 59, 10285−10290
10288
Although the magnitude of the PAINS problem is clearly
indicated by the results of our analysis, it should be noted that
PAINS alerts do not necessarily disqualify compounds from
further consideration or invalidate available data. Furthermore,
no compound can a priori be disqualified as a bioactive
chemical entity if it is potentially reactive or fluorescent. These
issues further complicate the assessment of compound
liabilities. There are numerous instances of compounds
containing PAINS motifs with true activities including a
number of marketed drugs.28 Whether or not potentially
reactive compounds give rise to artifacts often depends on
specific experimental conditions and modes of action.
Furthermore, although promiscuity degrees of bioactive
compounds are in our experience often overestimated by
taking low-confidence data into consideration, there is no doubt
that compounds frequently display multitarget activities that
result in side effects or desirable polypharmacology. Our
analysis also identified a subset of highly promiscuous
compounds for which no chemical liabilities were evident.
Thus, although we cannot rule out the presence of other
sources of artifacts that might be associated with at least some
of these compounds, they are likely to represent interesting
starting points for further exploring the molecular basis of
polypharmacology. Similarly, reactive compounds not detected
by PAINS filters provide opportunities for further studying
origins of assay interference.
As a part of our study, all highly promiscuous compounds
and the structural analogues we identified are made freely
available as an open access deposition together with their target
annotations and PAINS/aggregator detection status.29 These
compounds should be useful for further developing detection
methods and exploring molecular detail of “good” or “bad”
promiscuity.
■ METHODS AND MATERIALS
PubChem Data Collection. Assay data were extracted from the
PubChem BioAssay collection16 containing primary and confirmatory
assays. RNA interference (RNAi) screens were removed from primary
assays, and only chemical screens were considered. Confirmatory
assays were required to have specified compound activity values for
individual protein targets resulting from dose−response curves
(typically IC50 values). From each qualifying assay, compounds
classified as “active” or “inactive” were selected and molecules
designated as “unspecified” or “inconclusive” were disregarded.17
ChEMBL High-Confidence Activity Data. In ChEMBL version
21,13 all compounds were identified for which high-confidence activity
data were available. We required the presence of direct interactions
(i.e., assay relationship type “D”) with human single-protein targets at
the highest confidence level (i.e., assay confidence score 9).
Relationship type “D” and confidence score 9 represent the highest
level of confidence for activity data from ChEMBL. In addition, only
explicitly specified equilibrium constants (Ki) and IC50 values were
considered as potency measurements. All approximate measurements
such as “>”, “<”, or “∼” and activity records including comments such
as “inactive”, “inconclusive”, or “not active” were discarded. This
protocol identified 174,839 qualifying compounds.
Because ChEMBL incorporates assay data from PubChem, these
data were also filtered according to high-confidence criteria and
distinguished from activity data originating from the medicinal
chemistry literature.
Promiscuity Analysis. Target annotations were determined on
the basis of assay activity records (PubChem) and high-confidence
activity data (ChEMBL). The PD of a compound was defined as the
number of unique targets it was reported to be active against. The PD
was initially calculated on the basis of PubChem annotations and
adjusted if additional targets were identified in ChEMBL.
PAINS and Aggregators. Promiscuous compounds were
screened for PAINS using three public PAINS filters available in
RDKit,12 ChEMBL,13 and ZINC.14 Compounds were represented as
canonical SMILES on the basis of hydrogen suppressed graphs and
submitted to the respective filters. We note that ChEMBL does not
provide an interactive filter but lists PAINS annotations in compound
records instead, from which they can be retrieved. Following PAINS
filtering, compounds were also screened for known aggregators using
the ZINC aggregator filter.15
Analogue Search. Analogue searching in ChEMBL was carried
out using a recently reported matched molecular pair-based method-
ology.18
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(23) Arrońiz, C.; Molina, J.; Abaś, S.; Molins, E.; Campanera, J. M.;
Luque, F. J.; Escolano, C. First Diastereoselective [3 + 2]
Cycloaddition Reaction of Diethyl Isocyanomethylphosphonate and
Maleimides. Org. Biomol. Chem. 2013, 11, 1640−1649.
(24) Dahlin, J. L.; Nissink, W. M.; Strasser, J. M.; Francis, S.; Higgins,
L.; Zhou, H.; Zhang, Z.; Walters, M. A. PAINS in the Assay: Chemical
Mechanisms of Assay Interference and Promiscuous Enzymatic
Inhibition Observed during a Sulfhydryl-Scavenging HTS. J. Med.
Chem. 2015, 58, 2091−2113.
(25) Tabrizi, L.; Fooladivanda, M.; Chiniforoshan, H. Copper(II),
Cobalt(II) and Nickel(II) Complexes of Juglone: Synthesis, Structure,
DNA Interaction and Enhanced Cytotoxicity. BioMetals 2016,
DOI: 10.1007/s10534-016-9970-0.
(26) Anastassiadis, T.; Deacon, S. W.; Devarajan, K.; Ma, H.;
Peterson, J. R. Comprehensive Assay of Kinase Catalytic Activity
Reveals Features of Kinase Inhibitor Selectivity. Nat. Biotechnol. 2011,
29, 1039−1045.
(27) Olson, M. E.; Abate-Pella, D.; Perkins, A. L.; Li, M.; Carpenter,
M. A.; Rathore, A.; Harris, R. S.; Harki, D. A. Oxidative Reactivities of
2-Furylquinolines: Ubiquitous Scaffolds in Common High-Through-
put Screening Libraries. J. Med. Chem. 2015, 58, 7419−7430.
(28) Senger, M. R.; Fraga, C. A. M.; Dantas, R. F.; Silva, F. P., Jr.
Filtering Promiscuous Compounds in Early Drug Discovery: Is It a
Good Idea? Drug Discovery Today 2016, 21, 868−872.
(29) https://zenodo.org/record/164405
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.6b01314
J. Med. Chem. 2016, 59, 10285−10290
10290
Conclusions
Herein, highly promiscuous compounds were explored with respect to their
chemical integrity and potential usability in polypharmacology. A set of 466
compounds displaying the highest degrees of promiscuity in primary and con-
firmatory biological screening assays has been identified and was submitted to
structural filters. A majority of those were detected as colloidal aggregators or
PAINS, classifying them as exemplary cases of undesired promiscuity.
The remaining 189 compounds were visually inspected and false-negative
PAINS as well as compounds with other potential liabilities were identified. These
results revealed potential challenges with PAINS implementations that do not
address tautomerism and do not fully cover chemical liabilities, including autoflu-
orescence and chelation. Additional high-confidence activity annotations were
available for both detected PAINS and compounds passing structural filters. This
indicated that high-confidence activity data displayed a necessary but not suffi-
cient prerequisite for compound integrity. Finally, 30 highly promiscuous com-
pounds were identified for which no chemical liabilities were evident, providing a
starting point for further research in the field of polypharmacology.
In this study, the knowledge-based analysis of extensively tested screening
compounds showed that promiscuity degrees and structural filters alone are not
sufficient indicators of the quality for a compound’s promiscuity. Thus, upon the
utility of promiscuous compounds for polypharmacology must often be decided
on a case-by-case basis. In the next chapter, we explore crystallographic protein-
ligand complexes for known PAINS and draw first structure-activity relationships
between interference compounds.
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3 X-ray Structures of Target-Ligand
Complexes Containing Compounds
with Assay Interference Potential
Introduction
Assay artifacts compromise medicinal chemistry programs and false-positive
activities make it difficult to identify genuinely promiscuous compounds. To ad-
dress this, problematic PAINS classes were proposed as structural alerts for assay
interference, which requiere caution when they occur as substructures in bioac-
tive molecules. However, rationalizing and predicting interference compounds
remains difficult, as PAINS have been demonstrated to exhibit heterogeneous
activities and varying hit rates. These results indicated that PAINS activities are
not exclusively attributed to undesired interference mechanisms.
In this work, the analysis of PAINS is extended beyond biological assays and X-
ray crystallographic protein-ligand complexes containing compounds with known
interference potential are systematically studied. Further, interactions with target
proteins are examined on the basis of structural data and different modes of action
of PAINS are explored.
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Compounds with Assay Interference Potential
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ABSTRACT: Pan assay interference compounds (PAINS)
have become a paradigm for compound classes that might
cause artifacts in biological assays. PAINS-defining substruc-
tures are typically contained in larger compounds. We have
systematically examined X-ray structures of protein−ligand
complexes for compounds containing PAINS motifs. In 2874
X-ray structures, 1107 unique ligands with PAINS sub-
structures belonging to 70 different classes were identified.
PAINS most frequently detected in crystallographic ligands
included a number of prominent candidates such as quinones, catechols, or Mannich bases. However, on the basis of X-ray data,
the presence of specific ligand−target interactions and reactivity under assay conditions were not mutually exclusive. In some
instances, reactivity of ligands was likely responsible for complex formation. Different categories of PAINS-containing ligands
were distinguished, which aided in the interpretation of specific interactions versus potential assay artifacts. Careful consideration
of structural data adds another dimension to the analysis of interference compounds.
■ INTRODUCTION
In biological screening and medicinal chemistry, newly
identified active compounds and candidates for chemical
optimization must be distinguished from others that cause
assay artifacts. False-positive activity signals might be due to
colloidal aggregation1−3 or reactivity under assay conditions.4
Various mechanisms of assay interference have been suggested
including, among others, covalent modification of target
proteins, autofluorescence, redox reactivity, or chelation.4,5
Systematic attempts have been made to identify and collect
potential aggregators3 or compounds that cause assay artifacts
due to reactivity or autofluorescence,4 leading to the
introduction of pan assay interference compounds
(PAINS).4,5 The latter include intensely studied chemical
classes such as rhodanines, quinones, or curcuminoids.4−6
PAINS-defining moieties are typically contained as substruc-
tures in other compounds.
There is no doubt that assay interference represents a major
problem for biological screening and medicinal chemistry.7
However, rationalizing and predicting assay interference
potential or molecular promiscuity are far from being simple
tasks.8−12 For example, it has been shown that compounds with
PAINS substructures often had very different activity profiles in
screening assays and also contained a variety of chemical
entities that were consistently inactive.10,11 It is very likely that
the structural environment of PAINS substructures or other
reactive moieties in compounds plays a critically important role
for their potential to elicit artifacts.10−12 Substantial evidence
for this premise was provided by the study of analog series
containing PAINS substructures, which made it possible to
evaluate PAINS in different structural contexts.12 For example,
a number of analog series containing Mannich bases, aniline
derivatives, or alkylidine barbiturates were consistently inactive
in screening assays, whereas others contained frequently active
compounds.12 Furthermore, structural modifications at a single
site of notorious PAINS such as rhodanine or indol derivatives
strongly influenced their assay hit rates.12 In addition to PAINS,
many other compounds have interference potential.8,9 How-
ever, even for some highly promiscuous molecules, no evidence
or indications of possible assay artifacts exists.8 Clearly,
relationships between inactivity, specific activity, and artificial
activity of compounds with potential liabilities are often highly
complex and difficult to unravel.
To further extend the analysis of compounds with
interference potential beyond biological assays, we have
searched X-ray structures of target−ligand complexes for
compounds with PAINS substructures. The formation of
complexes that can be crystallized is usually driven by specific
interactions, which are revealed by X-ray structures. The
presence of specific interactions between a ligand and a given
target does not preclude desired or undesired interactions with
other targets. Importantly, complex structures containing
PAINS can be examined for modes of action, which can then
be related to potential reactivity and artifacts, hence providing a
new reference frame for judging interference potential.
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■ MATERIALS AND METHODS
X-ray Structures. Complex X-ray structures were selected from
the Ligand Expo section13 of RCSB Protein Data Bank (PDB),14
which provides standardized ligands.13 X-ray structures were graphi-
cally analyzed using the Molecular Operating Environment.15
Compounds extracted from X-ray structures (PDB ligands) were
Figure 1. Classification of PAINS found in X-ray structures. (a) The distribution of PDB_PAINS over 70 PAINS classes is shown in a histogram
format. Bins report the number of PDB_PAINS per class. In (b), 12 PAINS classes are shown that were each present in more than 20 PDB_PAINS.
Numbers in parentheses report the number of X-ray ligands belonging to a given PAINS class and the number of complexes in which they occurred.
For example, (194/447) means that there were 194 PDB_PAINS belonging to class catechol_A that occurred in 447 complex structures. In (c) and
(d), box plots report the distribution of crystallographic resolution (Å) and free R-values for all X-ray complexes with PAINS, respectively. Boxplots
report the smallest value (bottom line), first quartile (lower boundary of the box), median value (thick line), third quartile (upper boundary of the
box), and largest value (top line).
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represented as aromatic nonstereo SMILES.16 Proteins from X-ray
structures were assigned to families on the basis of UniProt identifiers
(IDs) and the UniProt classification scheme.17
PAINS Analysis. PDB ligands were screened in silico for
compounds containing PAINS substructures (PDB_PAINS) using
SMARTS18 strings obtained from three public filters available in
ChEMBL release 23,19 RDKit,20,21 and ZINC.22 Given possible
implementation discrepancies of substructure strings, compounds were
classified as PAINS if one or more filters yielded an alert. All
calculations were carried out using Python scripts with the aid of the
OpenEye chemistry toolkit,23 RStudio,24 and KNIME.25
PAINS filters are often viewed controversially10 as indicators of
assay interference.10−12 However, they provide direct access to
compound classes with potential liabilities classified as PAINS.7,11 As
such, their application was consistent with the goals of our analysis.
■ RESULTS AND DISCUSSION
PAINS in PDB Ligands. From PDB entries, we extracted
22,467 ligands with unique structures. These PDB ligands
contained 1107 PDB_PAINS that were present in a total of
2874 complex X-ray structures. This was a much larger number
of complex structures containing PAINS than we had expected.
The 1107 PDB_PAINS covered 70 of the 480 originally
proposed PAINS classes.4 Figure 1a shows the distribution of
PDB_PAINS over PAINS classes. The 12 classes of PAINS
substructures most frequently detected in PDB ligands are
shown in Figure 1b. Notably, these classes contained prominent
PAINS such as quinones, catechols, or Mannich bases.5
Furthermore, for 78 PDB_PAINS, complex structures with
different targets were available including 40 ligands with targets
from different families. Hence, for these PDB_PAINS there was
evidence for specific multitarget activity, as further discussed
below.
X-ray Structures with PAINS and Their Analysis. The
2874 X-ray structures containing PDB_PAINS were analyzed
in detail including one-by-one visual inspection. Following
initial inspection, 119 X-ray complexes with low resolution
were omitted from further consideration, yielding a final set of
2755 structures for detailed analysis. The PDB IDs of these X-
ray structures and 1094 corresponding PDB_PAINS are made
freely available in an open access deposition, as further specified
below.
Figure 1c,d reports the crystallographic resolution and free R-
values for the X-ray complexes, respectively, revealing that the
majority of structures were well-refined at medium to high
resolution, with a median value of 2.0 Å. We emphasize that
care must be taken to avoid overinterpretation of X-ray data,
taking resolution limits, potential local disorder, and refinement
ambiguities into account, which are not necessarily reflected by
global statistics. Structure factors and resulting electron
densities are experimental observations, not the atomic models
fitted into densities. At a resolution lower than 2 Å, it is
becoming difficult to distinguish between covalent and
noncovalent bonds, and case-by-case decisions must be made
during refinement, which complicates the verification of
covalent inhibition on the basis of X-ray structures. These
caveats generally apply and must also be taken into
consideration in analyzing complexes with PAINS. As discussed
above, reactivity under assay conditions does not by default
result in covalent inhibition of PAINS, which only applies to a
subset of reactive compounds. In fact, on the basis of visual
inspection of our collection of X-ray structures with PAINS, the
majority of complexes formed were clearly noncovalent. On the
other hand, the formation of a noncovalent complex does not
preclude reactivity of a compound under different conditions. It
proves, however, that a ligand is capable of forming specific
interactions with a given target. Formally, it is also possible that
cocrystallization might select nonreactive over reactive
compounds. Hence, even at the level of well-refined crystallo-
graphic models of complexes, the analysis of desirable versus
undesirable activities remains complex and overconclusions
must be drawn with caution.
Figure 2. Structures containing prominent interference compounds. Shown are exemplary X-ray structures with PDB_PAINS (carbon atoms colored
green) that contain prominent PAINS substructures known to frequently cause assay artifacts. Protein backbone ribbons and carbon atoms of
protein residues are colored in gold or silver. Other ligand and protein atoms are shown using standard atom coloring. Residues discussed in the text
are labeled. In molecular graphs of ligands, PAINS substructures are colored red. Names of target proteins, PAINS codes, and potency values (if
available in the literature) are provided. Figures 3−6 are presented accordingly. (a) Two unsaturated rhodanine derivatives are bound to the β sliding
clamp protein (PDB ID 3D1G, resolution: 1.64 Å, free R-value: 0.296) and bacterial MurD ligase (2Y68, 1.49 Å, 0.204), respectively. (b) Two p-
hydroxyphenylsulfonamides in complex with heat shock protein HSP 90-α (2YE9, 2.2 Å, 0.289) and cytohesin-2 (4JMO, 1.8 Å, 0.210).
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01780
J. Med. Chem. 2018, 61, 1276−1284
1278
PDB_PAINS Categories. On the basis of visual inspection
of the large number of PAINS-containing complex structures,
different categories of PDB_PAINS were identified that were
recurrent among X-ray structures. This made it possible to
rationalize interactions of PAINS with different targets in light
of assay interference potential, which represented a prime
motivation for our study. In the following, exemplary structures
are discussed that are representative of different categories of
PDB_PAINS we identified.
Prominent Interference Motifs. PAINS substructures that
are known to frequently cause assay artifacts were found in a
variety of complex structures. For instance, five-membered
heterocycles such as rhodanines are among notorious PAINS,5
for which reactions with protein residues have been observed26
including attacks by protein nucleophiles27 or metal chelation.28
The interference potential of rhodanines has been investigated
in different structural environments, indicating a context
dependence of reactivity.12,29 On the other hand, rhodanines
have also been put forward as “privileged scaffolds” for drug
discovery.30 Figure 2a shows two representative unsaturated
rhodanines (PAINS code4 ‘ene_rhod_A’) that contribute to
specific molecular interactions in X-ray structures with different
targets. For example, in subsite 1 of the β sliding clamp
protein,31 the carbonyl oxygen of the rhodanine heterocycle
participates in a water-mediated hydrogen-bond network with
the residue Arg152. Furthermore, the terminal arylidene moiety
of rhodanine in complex with UDP-N-acetylmuramoyl-L-
alanine:D-glutamate ligase32 occupies the uracil-binding pocket
and participates in a salt bridge interaction with residues Asp35
and Arg37.
Another prominent PAINS class are p-hydroxyarylsulfona-
mides that have redox activity33 and the ability of covalent
modification34 and degradation.35 The p-hydroxyarylsulfona-
mides typically only display assay interference if they contain a
naphthalene core.35 Figure 2b shows two examples of p-
hydroxyarylsulfonamides from fragment-based drug design
campaigns with and without a naphthalene substructure that
have distinct binding modes. In a complex with heat shock
protein 90,36 one sulfonamide oxygen forms a hydrogen bond
with Lys58. Alternatively, the phenolic hydroxyl group acts as
an anchor in the Sec7 domain of cytohesin-2, a guanine
nucleotide exchange factor,37 where it forms hydrogen bonds
with the carbonyl oxygen of Leu148 and the backbone amide of
Leu153.
Crucial Interactions Distinct from Interference Potential. A
number of cases were identified in which specific activity of
PAINS substructures could be attributed to crystallographically
observed interactions that were distinct from molecular origins
of assay interference. For example, fluorescent dyes such as the
9-aminoacridine derivative shown in Figure 3a are potent DNA
intercalating agents38 that can act as topoisomerase inhibitors
and mutagenic agents.39 While the X-ray structure of its
complex with DNA validates the contribution of the
chromophoric acridine moiety to DNA intercalation, there is
no doubt that photoinduction of 9-aminoacridines can cause
false-positive signals in photometric and fluorometric assays.40
Catechols represent another prime PAINS motif that is not
only present in synthetic compounds but also widely
distributed among natural products.41 The tendency of
catechols to chelate metals, their redox activity, and reactivity
against nucleophiles in oxidized form cause frequent assay
artifacts.5,41 However, catechols also have other potential
activities. For example, norathyriol, the aglycon of the natural
product mangiferin, is an ATP site-directed inhibitor of
mitogen-activated protein kinase 1 (ERK2).42 Figure 3b
shows that the 1,2-dihydroxyphenyl group of the bound ligand
forms three hydrogen bonds with the hinge region of ERK2
involving the side chain of Gln105 and the backbone carbonyl
oxygens of Asp106 and Met108. Hence, specific interactions are
responsible for an activity distinct from possible interference
effects.
Interference Reactions As a Mechanism Underlying
Protein Binding. Many interference mechanisms are reported
to rely on complexation or covalent modification of target
proteins.5,35,41 Thus, it was particularly interesting to discover
compounds that result from corresponding reactions and bind
to different targets. For example, Figure 4a shows a covalently
bound inhibitor of macrophage migration inhibitor factor
(MIF).43,44 This quinolol-type ligand contains a 2-hydrox-
ybenzylamine substructure that has undesirable Mannich base
reactivity leading to chelation of metal ions45 or formation of
reactive quinone methides, which are prone to unspecific
nucleophilic attacks.46 Furthermore, Cisneros et al. have shown
that 2-hydroxybenzylamine containing compounds covalently
inhibit MIF, giving rise to discrepancies in different assays.47 In
the MIF complex shown in Figure 4a, the formation of a
Michael acceptor intermediate with subsequent nucleophilic
attack of the Pro1 nitrogen generated the observed covalent
protein−inhibitor complex. Hence, in this case, a Michael-type
reaction led to modification of a PAINS motif and inhibition.
Depending on the assay setup, signals caused by compounds
that might be colored should be carefully evaluated.
Interestingly, for some colored compounds, additional
interference mechanisms are reported. For instance, azo
compounds are well-known dyes but may also undergo light-
or X-ray-induced photolysis and react with biological
nucleophiles, resulting in the formation of covalent
bonds.48,49 Such a bond was formed between an azo
compound, a known protein−protein interaction inhibitor,
and Lys120 of the 14-3-3 protein ζ/δ,50 shown in Figure 4b.
Zhao et al. proposed that radiation exposure of this molecule
caused diazene bond cleavage.50 The resulting pyridoxal-
Figure 3. Interference motifs forming crucial interactions. (a) An
aminoacridine derivative in complex with DNA (1KCI; 1.8 Å, 0.291,
DNA carbon atoms colored gold). (b) Norathyriol bound to the ATP
site of mitogen-activated protein kinase 1 (3SA0, 1.59 Å, 0.200).
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01780
J. Med. Chem. 2018, 61, 1276−1284
1279
phosphate moiety was anchored by hydrogen-bond interactions
with Asp124 and Asn173, correctly positioning the reactive
nitrogen for a nucleophilic attack by residue Lys120.
Ring opening reactions and subsequent degradation also
cause assay interference. For rationalizing such effects, the
structure of a complex of metallo-β-lactamase type 2 with an
arylidene rhodanine inhibitor crystallized in a degraded state51
was highly instructive, shown in Figure 4c. Following
hydrolysis, the resulting thioenolate formed a network of
specific interactions in the active site of β-lactamase. The thiol
function bridged the two zinc cations and the carboxylate
moiety of Asp120, while the carboxylate oxygen of the ligand
interacted with one of the zinc cations, the thiol group of
Cys221, and the side chain nitrogen of His263. Hence,
interference reactions might also lead to specific inhibition,
which could be a more general way in which, for example,
rhodanine-type ligands might interact with different targets.
Exploring the Structural Context Hypothesis. The analysis
of analog series containing PAINS substructures has provided
substantial support for the dependence of PAINS reactivity on
Figure 4. Interference mechanisms lead to binding. Shown are structures of complexes formed on the basis of PAINS reactivity. Reactions involving
PAINS motifs that result in compounds forming specific interactions are summarized. (a) Covalent reaction of a Mannich base leads to alkylated
macrophage migration inhibitor factor (3JSF, 1.93 Å, 0.218). (b) Cleavage of a diazene bond and subsequent formation of a covalent bond with 14-
3-3 protein ζ/δ (3RDH, 2.39 Å, 0.287). (c) Generation of a zinc cation complexing metallo-β-lactamase type 2 inhibitor following hydrolysis of a
rhodanine (4PVO, 1.48 Å, 0.165).
Figure 5. Structural context of PAINS motif. Examples of analogous PDB_PAINS are shown in which the PAINS substructure is presented in a
structural context that restricts reactivity, leading to the formation of specific interactions with different targets. (a) Two rhodanine derivatives
containing an oxindole ring in complexes with poly(ADP-ribose) glycohydrolase (4EPQ) and B-cell lymphoma 6 protein (3LBZ, 2.3 Å, 0.269). (b)
Mannich bases with a piperidinyl moiety in complexes with cellular tumor antigen p53 (5ABA, 1.62 Å, 0.203) and polyketide synthase Pks13 (5V3X,
1.94 Å, 0.247).
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the structural context in which they are presented.12 This
context hypothesis can also be investigated at the X-ray
structural level. For example, Figure 5a shows two ene_r-
hodanine-type ligands that were crystallized with poly(ADP-
ribose) glycohydrolase (PARG)52,53 and B cell lymphoma 6
protein (BCL6).54 Both inhibitors were highly similar and
shared a central unsaturated rhodanine heterocycle that was
substituted with an aliphatic carboxyl moiety at the nitrogen
and an oxindole ring at the unsaturated carbon. Given this
structural context, the rhodanine heterocycle was not reactive
and contributed to binding. In both complexes, the inhibitors
were sandwiched via π−π stacking interactions between the
oxindole function and corresponding tyrosine and phenyl-
alanine residues. The rhodanine ring was deeply bound in the
ADP binding region of PARG and the lateral groove of BCL6,
respectively.
Figure 5b shows complexes of cellular tumor antigen p53 and
polyketide synthase PKs13 with phenolic Mannich bases
possessing a tertiary amine as a part of an aliphatic piperidine
ring system. In these structures, the positively charged tertiary
amine contributes to charge assisted hydrogen bonds with
aspartic acid and asparagine, respectively. In the p53 complex,
the hydroxyphenyl moietiy also contributes to backbone
interactions with corresponding leucine and tryptophan
moieties, while the hydroxypiperidin-1-yl ring remains solvent
exposed. Interference mechanisms associated with phenolic
Mannich bases such as chelation or the formation of reactive
quinone methides depend on steric properties and the ability of
the amine to act as a leaving group.45,46 However, this ability
was restricted in these cases. Therefore, different from other
phenolic Mannich bases, these compounds were not reactive
and interacted with both targets.
Multitarget Activity Across Different Families. Previously,
compounds forming X-ray complexes with targets from
different families were identified.55 We have also searched for
PDB_PAINS bound to targets from distinct families. For 40
PDB_PAINS, complexes with members of unrelated protein
families were identified. Among these were 3-alkylindoles that
may have Michael-type reactivity.4 The indole derivative shown
in Figure 6a was crystalized with myeloid cell leukemia protein
1 (Mcl-1).56 In this compound, the PAINS motif is part of a
tricyclic indole lactam that positions two ring systems for
specific interactions in its bound conformation. Subsequently,
binding of this compound to human serum albumin binding
(HSA) was investigated.57 Here, the rigid tricyclic indole lactam
is tightly bound to drug site 3 of HSA. The binding modes of
the ligand and its interaction patterns clearly differ for the
unrelated targets. Clearly, the observed promiscuity of this
indole derivative was not related to possible assay interference
mechanisms, but was due to specific interactions in distinct
binding sites resulting from the given structural embedding of
the PAINS motif.
Figure 6b compares X-ray structures of two complexes
involving the phenothiazine derivative chlorpromazine, which is
typically used as a probe for nicotinic acetylcholine receptors.
However, the structure of chlorpromazine in complex with
Erwinia ligand-gated ion channel revealed binding of the ligand
to an allosteric site.58 Furthermore, a structure of chlorproma-
zine in complex with unrelated mouse prion protein was also
available.59,60 Interestingly, the binding modes of chlorproma-
zine were similar in these cases, although the protein
environments and binding sites were distinct. In both cases,
the phenothiazine moiety served as a hydrophobic anchor in
lipophilic regions of the binding sites.
Examples such as the complex structures containing the 3-
alkylindole derivative or chlorpromazine confirm multitarget
activity of ligands with PAINS substructures and thus
rationalize the promiscuity of these compounds.
Figure 6. Activity of PDB_PAINS across distinct target families. Examples of PBD_PAINS are shown that form complexes with unrelated targets
yielding different or similar binding modes. (a) An indole derivative bound to myeloid leukemia cell protein 1 (5IF4, 2.39 Å, 0.218) and serum
albumin (5UJB, 2.7 Å, 0.215). The binding modes of the ligand differ. (b) Chlorpromazine, a phenothiazine derivative, in complexes with Erwinia
ligand-gated ion channel (5LG3, 3.57 Å, 0.253) and a mouse prion protein (4MA8, 2.2 Å, 0.236), displaying similar binding modes.
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■ CONCLUDING DISCUSSION AND SUMMARY
In this study, we have systematically searched for and examined
X-ray structures of target−ligand complexes with assay
interference compounds. Our reasoning was that X-ray
structures might provide most detailed information as to how
compounds classified as PAINS might interact with targets, by
desirable or undesirable mechanisms. Therefore, while very few
individual examples of crystallized PAINS ligands have been
noted,47,61 we have carried out a first systematic analysis of
PAINS in X-ray structures. A large number of crystallographic
ligands containing PAINS substructures were identified. Careful
analysis of these X-ray structures revealed different mechanisms
of action for PAINS. In some cases, prime candidates for assay
interference due to potential reactivity were found to form
specific interactions with targets. In others, PAINS-containing
ligands formed interactions that were not related to likely
causes of assay artifacts. Moreover, in other instances, PAINS
reactivity was responsible for the formation of specific target−
ligand complexes. Finally, a number of PDB_PAINS also
bound to unrelated targets, displaying either different or similar
binding modes. These findings provided a rationale for
promiscuity of such compounds as a consequence of specific
interactions with multiple targets.
As discussed, potential PAINS reactivity does not imply that
covalent complexes must be formed. We also note that
compound potency cannot be unambiguously correlated with
interactions seen in X-ray structures because potency results
from multiple effects including desolvation and entropic
contributions. This also needs to be taken into consideration
in interaction analysis.
On the basis of structural data, a differentiated picture of
possible PAINS effects was obtained. Clearly, the formation of
specific target−ligand interactions and the possibility of assay
artifacts were not mutually exclusive. Small chemical
modifications of PAINS substructures often restricted undesir-
able reactivity and enabled binding interactions, which provided
direct support for structural context dependence of PAINS
reactivity.
Together with the structural context dependency of PAINS
activity,12 the multifaceted picture of PAINS actions revealed at
the level of complex X-ray structures reinforces the use of
PAINS substructure filters, which are controversially
viewed,10,62,63 as an initial indicator of assay interference
potential. PAINS filters cannot detect compounds that are
certain to elicit artifacts.10,11 Rather, they provide valuable
structural alerts to raise awareness of potential caveats and
prioritize candidate compounds for follow-up investigations,11
which is well in accord with recommendations of leading
journals in medicinal chemistry and related fields.7
In summary, more than 1000 PDB_PAINS were detected in
nearly 3000 X-ray structures of ligand−target complexes.
Potentially reactive compounds were frequently found to
engage specific interactions with variety of targets. On the
basis of X-ray data, most complexes with PDB_PAINS were
noncovalent, but PAINS reactivity also resulted in the
formation of complexes including covalent inhibition. A
confined number of PDB_PAINS was found to form
complexes with unrelated targets adopting different binding
modes. Furthermore, X-ray structures of noncovalent com-
plexes with PDB_PAINS provided further evidence for
different embedding of PAINS-defining substructures in ligands
restricting intrinsic reactivity but not precluding binding events.
Moreover, many PDB_PAINS interacted with targets by
mechanisms that were distinct from confirmed or assumed
interference effects, demonstrating that specific binding and
assay interference were not mutually exclusive.
As an outlook, the unexpected wealth of structural data
available for ligands with PAINS substructures opens the door
for further mechanism of action investigations of PAINS and
other interference compounds. To these ends, PDB_PAINS we
identified are made freely available together with links to the X-
ray structures from which they originated.64
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Conclusions
By taking X-ray structure data into account, a further dimension for the analysis
of interference compounds was explored. In total, 70 different PAINS classes were
represented by 1107 unique ligands found in 2874 crystallographic complexes,
including prominent representatives such as rhodanines, catecholes, or Mannich
bases. Analysis of this complexes allowed us to reveal different modes of action.
Crucial ligand interactions were often found to be distinct from interference
potential and PAINS substructures contributed to specific target interactions. In
some instances, PAINS reactivity was even responsible for the formation of com-
plexes, for example, by covalent modification of target proteins. We also identified
a series of X-ray structures, in which chemical modifications of reactive PAINS
moieties restricted their ability to produce undesired chemical reactions. This
finding suggested that the structural context in which PAINS are represented
may play an important role for eliciting false-positive activities. The set of PAINS
crystallographic ligands is made freely available.
The results of this work demonstrate the multifaceted picture of PAINS ac-
tivities and provide a novel reference frame for the judgment of interference
potential and multitarget activities. Following the structural context hypothesis,
activity profiles of analog series containing PAINS are systematically identified
and analyzed in the next chapter. This allows us to draw structure-activity rela-
tionships of interference mechanisms based on the structural embedding of PAINS
substructures.
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4 Activity Profiles of Analog Series
Containing Pan-Assay Interference
Compounds
Introduction
Although there is no doubt that many PAINS generate false-positive activity
data, the application of structural alerts should not result in a automatically dis-
carding potential candidates for medicinal chemistry. For example, systematic
analyses of PAINS activity data have shown that interference compounds are
often specifically active or consistently inactive. Moreover, X-ray structures of
protein-PAINS complexes demonstrate that prominent PAINS engage in specific
binding interactions and that interference mechanisms often provide the basis for
target interactions. PAINS alerts intrinsically do not represent the entire structure
of a compound. Therefore, the aforementioned findings provide evidence that
the structural embedding of PAINS substructures plays a decisive role for assay
interference.
Herein, the structural context of PAINS is explored by performing a system-
atic analysis of analog series containing assay interference compounds. Activity
profiles of extensively tested PAINS and their structural analogs are compared.
My main contribution to this work was the generation of analogs series, identi-
fication of activity profiles, and the structural context analysis of PAINS activities.
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Activity profiles of analog series containing pan
assay interference compounds
Erik Gilberg, Dagmar Stumpfe and Ju¨rgen Bajorath *
Activity artifacts in assays present a major problem for biological screening andmedicinal chemistry. Such
artifacts are often caused by compounds that form aggregates or are reactive under assay conditions.
Many pan assay interference compounds (PAINS) have been proposed to cause false-positive assay
readouts. PAINS are typically contained as substructures in larger molecules. They are used as
computational filters to detect compounds with potential chemical liabilities. Recent studies have
shown that molecules containing the same PAINS substructure often have greatly varying hit rates in
screening assays. Even the overall most frequently active PAINS substructures are found in
compounds that are only rarely active or consistently inactive in many assays they are tested in. These
observations suggest that the structural context in which PAINS are presented may play an important
role for eliciting false-positive activities. However, this assumption remains to be investigated. Herein,
we report the systematic identification of analog series of screening compounds that contain PAINS or
exclusively consist of PAINS and the analysis of their activity profiles. Comparison of analogs or
different series of analogs containing the same PAINS substructure provides structural context
information. For many PAINS, extensively tested series with distinct activity profiles were detected.
Furthermore, analogs within the same series often displayed significant differences in hit rates. The
analog series reported herein organize PAINS in different structural contexts. Their activity profiles
provide many opportunities for experimental follow-up investigations to better understand PAINS
characteristics.
Introduction
Activity artifacts in biological screening assays can be caused by
compounds that are prone to colloidal aggregation1,2 or that are
chemically reactive under assay conditions.3,4 A variety of
mechanisms may lead to apparent inhibition and false-positive
signals including, among others, uorescence of small mole-
cules, redox reactivity, or covalent modications of target
proteins.4–6 Compounds with assay interference potential orig-
inate from both synthetic and natural sources7 and include
molecules that are intensely investigated in pharmaceutical
research.8
There is no doubt that assay artifacts compromise medic-
inal chemistry programs and that false-positive activities
cumulate in the scientic literature. This situation has trig-
gered community efforts to raise awareness of assay inter-
ference.9 Since it oen remains unclear if a compound causes
an articial activity signal, careful experimental follow-up
studies are required.2,9 One way to proactively address this
problem is the search for potential interference compounds
that require special attention if they are found to be active in
assays.10
In a landmark study, 480 chemical classes have been put
forward as candidates for assay interference.3 To these ends,
limited numbers of compounds were tested in AlphaScreen
assays.3 This set of so-called pan assay interference compounds
(PAINS)3 contains many small reactive chemical entities that
oen occur as substructures in larger molecules. While it
cannot be expected that PAINS cover the entire spectrum of
possible interference mechanisms, their identication has
made it possible to implement substructure lters to ag
potential interference compounds,3,10 an important step toward
the identication of questionable candidates.
However, the predictive value of PAINS lters has also been
called into question, given that for many of the proposed
structures only limited experimental support was available.11 In
general, although assay artifacts are a problematic issue,
excluding any potentially reactive compound from further
consideration would not be justiable scientically. Over-
estimating the magnitude of assay interference may lead to
disregarding compounds that have desired activities and/or act
by novel mechanisms.
Two recent studies, have systematically evaluated the activity
of PAINS on the basis of publicly available screening data11,12
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and other compound sources.11 Both investigations revealed
substantial heterogeneity in PAINS activities and greatly varying
hit rates. Furthermore, many rarely active or consistently inac-
tive molecules with PAINS substructures were detected.11,12
While small subsets of PAINS including, for example, quinones,
catechols, rhodanines, or Mannich bases oen represented
highly active compounds, most likely causing artifacts, other
classes of PAINS did not display unusual hit rates. Moreover,
even the most frequently active PAINS were also found in many
consistently inactive compounds. Taken together, these obser-
vations indicated that the molecular environment11 or struc-
tural context12 in which PAINS are presented might play an
important role for their ability to elicit desirable activities or
artifacts. However, little has been done so far to address the
question how structural embedding might modulate PAINS
activity.
Therefore, we have carried out a systematic analysis of
analog series containing PAINS, which provide structural
context information. Analog series were systematically extracted
from screening compounds. For series of extensively assayed
PAINS, activity proles were determined and studied in detail,
yielding rst insights into structural context-dependent modu-
lation of PAINS actions. The results of our analysis are pre-
sented in the following.
Methods and materials
Compound activity data
A subset of 437 257 screening compounds from PubChem
BioAssays13 that were tested in primary assays (percentage of
inhibition from a single dose) and conrmatory assays (dose–
response assays yielding IC50 values)14 provided our starting
point. PubChem compounds for which data from both primary
and conrmatory assays are available have usually been
frequently tested. Hence, most of the pre-selected molecules
were evaluated inmore than 50 assays. For our analysis, only the
most extensively assayed compounds were considered. There-
fore, the global distribution of the number of assays in which
the pre-selected compounds were tested was determined.
Fig. 1a shows this distribution in a boxplot format. PubChem
compounds that were tested in more than 257 primary assays,
corresponding to the lower quartile boundary of the distribu-
tion, were selected for our analysis, yielding a total of 327 523
compounds.
Identication of analog series
From these 327 523 compounds, analog series (ASs) were
systematically extracted using a recently developed method-
ology,15which is based upon thematchedmolecular pair (MMP)
formalism.16 MMPs are pairs of compounds that are only
distinguished by a chemical change at a single site,16 oen
termed a chemical transformation.17 To generate MMPs,
exocyclic single bonds in screening compounds were system-
atically fragmented following retrosynthetic fragmentation
rules,18 yielding RECAP-MMPs.19 Previously established trans-
formation size restrictions were introduced to limit
transformations in MMPs to chemical modications typically
observed in analogs.20 Once all possible RECAP-MMPs
were generated, a global MMP network was constructed in
which compounds were represented as nodes and edges
accounted for pairwise MMP relationships. In this network
representation, ASs form disjoint (isolated) clusters.15 Each
cluster contains all possible MMP relationships within a series,
which cover all substitution sites and available R-groups.
For 190 612 of the 327 523 extensively assayed compounds,
analog relationships were detected, resulting in the formation
of 34 300 individual clusters and ASs.
For each of the 34 300 ASs, assay and target information was
compiled. For each AS, assay overlap was determined as the
number of assays shared by all analogs. In addition, for pairwise
comparison of ASs, the overlap was calculated as the number of
assays common to both series.
Hit rate intervals and activity proles
The hit rate of a compound was conventionally dened as the
fraction of assays in which it was active. The distribution of hit
rates over all compounds was captured in a boxplot yielding
a median value of 0.4% (Fig. 1a). On the basis of this distribu-
tion, the interval of expected hit rates (hrexp) for active PubChem
screening compounds was dened as 0% < hrexp # 1.0%
covering the lower quartile, median, and upper quartile.
Accordingly, hit rates exceeding 1.0% (upper whisker and
outliers) were considered high. The lower whisker and lower
quartile boundary of the boxplot were identical and represented
consistently inactive compounds. Thus, activity proles were
dened on the basis of three hit rate intervals including
consistent inactivity (0%), expected or average hit rates (0% <
hrexp # 1.0%), and high hit rates (>1.0%) (Fig. 1a). Given that
qualifying compounds were tested in at least 258 assays, high
hit rates corresponded to activity in a minimum of three assays,
while expected hit rates of active compounds corresponded to
activity in one or two assays. Hence, as dened, the interval of
high rates predominantly focused on promiscuous compounds.
Apparent promiscuity might result from true multi-target
activities or assay artifacts. The distribution of hit rates
exceeding 1.0% was also monitored in boxplots for screening
compounds that did not contain PAINS substructures (non-
PAINS) and PAINS substructures (Fig. 1b).
The activity prole of an AS was then generated by
combining hit rates of all participating analogs, as illustrated in
Fig. 2.
Detection of pan assay interference compounds
Analog series were screened in silico for PAINS using three
public lters available in ChEMBL (481 substructures),21 RDKit
(480),22 and ZINC (480).23 For screening compounds, canonical
SMILES representations24 were generated. Compounds were
classied as PAINS if a PAINS substructure was detected by at
least one of the three lters (considering possible imple-
mentation discrepancies of substructure strings). Filtering
identied 177 different PAINS substructures in 3473 ASs.
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 35638–35647 | 35639
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All calculations were performed using in-house Java and R
scripts with the aid of KNIME25 protocols, the OpenEye26
chemistry toolkit, and RStudio.27
Control calculations
As a control, the analysis was repeated for ASs originating
from compounds tested in 65-247 conrmatory assays. In
this case, 3459 ASs with PAINS substructures were identied,
1865 of which exclusively consisted of PAINS. The analysis
of the activity proles of this set of series yielded results
that were readily comparable to those obtained for ASs
originating from primary assays. In the following, we
therefore concentrate on the results for ASs from primary
assays.
Fig. 1 Assay frequency and hit rate distribution. (a) At the top, a boxplot shows the primary assay frequency distribution for 437 257 pre-selected
PubChem compounds. Only compounds tested in more than 257 primary assays (lower quartile boundary) were considered for further analysis.
At the bottom, the hit rate distribution for these 327 532 compounds is shown in another boxplot on the basis of which hit rate intervals were
defined, as detailed in the text. In (b), the hit rate distribution of compounds with hit rates above 1% is shown in boxplots for screening compounds
without PAINS substructures (non-PAINS, left) and PAINS (right).
35640 | RSC Adv., 2017, 7, 35638–35647 This journal is © The Royal Society of Chemistry 2017
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Results and discussions
Analog series with PAINS
For 190 612 of 327 532 PubChem compounds tested in at least
257 primary assays, analog relationships were identied,
yielding a total of 34 300 ASs. Compound and AS statistics are
reported in Fig. 3 (bottom). PAINS were detected in 13 018
compounds from 3473 ASs. More than half of these ASs, i.e.
1876 series comprising 7969 compounds, exclusively consisted
of PAINS. These ASs contained two to 190 analogs with on
average four PAINS per series. In all ASs with PAINS, 177 of the
480 PAINS substructures were detected. ASs exclusively con-
sisting of PAINS covered 140 different substructures. Further-
more, for 32 PAINS substructures, at least 10 ASs were
identied. Thus, overall, a large number of PAINS-containing
ASs was available, providing an extensive structural organiza-
tion of PAINS and a sound basis for our analysis.
Targets
For the ASs belonging to the three different categories according
to Fig. 3 target statistics were determined. We found that 7.3%
of the ASs exclusively consisting of PAINS and 6.9% of ASs
comprising PAINS and non-PAINS were only active against
a single target (ST-ASs). For ASs only consisting of non-PAINS,
the proportion of ST-ASs was 13.6%. Thus, most ASs in all
three categories were multi-target ASs (MT-ASs). ST- andMT-ASs
exclusively consisting of PAINS were active against a total of 385
unique targets, while ST- and MT-ASs with PAINS and non-
PAINS covered 401 targets. In addition, non-PAINS ST- and
MT-ASs were active against a total of 418 targets. Thus, target
coverage of all three categories of ASs was extensive and
comparable in magnitude. Notably, the 1873 ASs only consist-
ing of PAINS were active against nearly as many targets (92.1%)
as the 16-fold larger number of non-PAINS ASs.
Hit rates
Fig. 1a shows the distribution of hit rates of extensively assayed
PubChem compounds on the basis of which hit rate intervals
were determined, as detailed above. In addition, Fig. 1b
compares the distribution of hits rates for those non-PAINS and
PAINS having rates exceeding 1.0%. More than 75 000 non-
PAINS had hit rates greater than 1.0% compared to 5115
Fig. 2 Activity profiles and exemplary analog series. At the top, all possible activity profiles are displayed that represent different combinations of
the three hit rate intervals according to Fig. 1a (consistently inactive, red; expected hit rates, yellow; high hit rates, green). Below the profiles,
compounds forming two different ASs containing the same PAINS substructure (red) are shown. For each analog, the hit rate and corresponding
interval are given and the resulting activity profile of the series is displayed.
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 35638–35647 | 35641
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compounds with PAINS substructures. Thus, 60.7% of all PAINS
from ASs (7903 compounds) were consistently inactive or only
active in one or two assays. As one would anticipate, within the
hit rate interval exceeding 1.0%, PAINS had overall higher hit
rates than non-PAINS but the differences were only small. As
shown in Fig. 1b, the hit rate distributions were similar for
PAINS and non-PAINS, with median values of slightly above and
below 2.0%, respectively. Taken together, these observations
made for PAINS with analog relationships corroborated earlier
ndings from global PubChem analysis.11,12 For all ASs with
PAINS, activity proles were generated from their assay data.
Activity proles
Fig. 2 depicts the seven possible activity proles for ASs that
account for hit rate intervals and their combinations. Two
exemplary ASs are shown. All analogs belonging to AS 1 were
active and had high hit rates, resulting in the ‘green-only’ prole
of the series. By contrast, four of ve analogs of AS 2 were active
and one consistently inactive. Two of the active analogs had
high and two others expected hit rates. Thus, the activity prole
of the series was the combination of all three intervals (‘green-
yellow-red’).
Activity proles were systematically determined for all 34 300
ASs extracted from extensively assayed PubChem compounds.
Therefore, the ASs were divided into three subsets: analogs
having no PAINS substructures (30 827 series), analogs with and
without PAINS substructures (1597), and analogs always con-
taining PAINS (1876). Fig. 3 reports the distribution of these AS
subsets over different activity proles in a histogram. Consis-
tently inactive ASs (‘red-only’ prole) and ASs containing
compounds having high rate rates and inactive analogs (‘green-
red’) were rare. By contrast, nearly 30% of ASs exclusively con-
sisting of PAINS displayed the ‘green-only’ (high hit rate) prole,
which was a much larger proportion than obtained for the other
two AS subsets (with close to 10%). Essentially inverse propor-
tions were observed for ASs containing consistently inactive as
well as active compounds with expected hit rates (‘yellow-red’).
Furthermore, more than 30% of ASs with non-PAINS and PAINS
yielded the complete (‘green-yellow-red’) activity prole. Hence,
these series contained analogs covering all hit rate intervals.
Notably, about 55% of ASs exclusively consisting of PAINS
yielded activity proles covering multiple hit rate intervals,
revealing that analogs with a given PAINS substructure oen
had different activities.
Fig. 4 shows the distribution of activity proles for 32 PAINS
for which 10 or more ASs were available that exclusively con-
tained this PAINS substructure. Thus, this subset of PAINS was
most frequently found in ASs. It included widely recognized
PAINS such as anilines, rhodanines, or quinones.4 The heatmap
reveals the prevalence of the ‘green-only’ and ‘green-yellow’
proles among the ASs of this subset of PAINS. However, the
heatmap also shows that activity proles were variably distrib-
uted across ASs with different PAINS. For example, the ‘yellow-
red’ and complete activity proles were also frequently
observed. Hence, prevalent PAINS also displayed varying activ-
ities in ASs.
Fig. 3 Distribution of activity profiles for analog series of different composition. Global distributions of activity profiles for ASs exclusively
consisting of PAINS (dark blue bars), combinations of PAINS and non-PAINS (blue), and only non-PAINS (light blue) are reported. At the bottom,
compound and series statistics are provided.
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Context-dependent structure–activity relationships
The ASs containing PAINS substructures provided a series-
based organization and reference frame for analyzing and
comparing the activity of PAINS in different structural envi-
ronments. A variety of interesting and in part puzzling rela-
tionships was observed.
Fig. 5a compares two rhodanine-based series with distinct
hit rates and activity proles. These ASs were tested in more
than 300 assays with an assay overlap of 98%. Compounds
forming the series on the le were at most active in a single
assay, whereas compounds in the series on the right were active
in six to eight assays. Both ASs shared a 5-phenylmethylen-3-
rhodanine acetamide substructure that was modied at the
nitrogen of the acetamide. Analogs in the series on the le had
a tetrahydrothiophene-1,1-dioxide substituent in common,
while the frequently active compounds in the ASs on the right
shared a 2-(3-pyridinyl)-piperidine. Biologically relevant reac-
tivities of rhodanines and related heterocycles have been
intensely investigated and several plausible mechanisms of
action have been proposed.28 Oen considered is a Michael
addition via the exocyclic double bond.29 In this case, observed
differences in activity could not be attributed to a Michael-type
reaction because the same rhodanine derivative occurred in
both ASs. Instead, possible photochemical30 or hydrolytic31
reactivity might be modulated by different substituents at the
acetamide.
Fig. 5b depicts two ASs sharing a 3-methyl-indole core.
Similar to the previous example, analogs forming the series on
the le were only active in at most one assay, while analogs of
the series on the right were active in ve to nine assays. This was
the case although the AS on the le was more extensively tested
than the one on the right (in more than 500 vs. 300 assays).
Different from the previous example, substitution patterns were
more diverse here. Baell et al. discussed that 3-alkylindoles and
indole-3-acetamide-2-carboxylic acids likely act as Michael
acceptors and thereby cause artifacts.3However, in this case, the
rarely active analogs in the ASs on the le contained a carboxylic
acid function, which was replaced by a methyl group in the
frequently active series on the right. Thus, the activity proles of
these ASs were opposite to expectations considering potential
Michael acceptor reactivity.
Fig. 5c compares two series of 2-hydroxybenzylamine deriv-
atives, one of which was consistently inactive in many assays
(le), whereas analogs forming the other (right) were active in
nine, 15, and 20 assays, respectively. Such high hit rates are
likely to involve artifacts. The 2-hydroxybenzylamines may act as
Mannich bases and elicit undesired activities by forming reac-
tive quinone methides32 or by chelating metal ions.33 However,
the striking difference in activity between these two ASs was not
straightforward to rationalize. Notably, the 2-hydroxybenzyl-
amine moiety in the series on the le was located at the
terminus of the analogs, whereas it was fused with a pyridine
Fig. 4 Activity profile distribution for different PAINS. Activity profiles
of ASs containing the same PAINS substructure are displayed in
a heatmap. Each column corresponds to a given activity profile and
each row represents an individual PAINS (sub)structure. Empty cells
(white) indicate the absence of a profile. Occupied cells are color-
coded according to increasing numbers of ASs displaying the same
profile using a spectrum from light to dark blue. The heatmap only
contains 32 PAINS with at least 10 different ASs. PAINS were ordered
according to increasing numbers of ASs. Rows of PAINS for which
specific examples are discussed in the text are numbered in red and
these PAINS are specified below the heatmap.
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 35638–35647 | 35643
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Fig. 5 Analog series with PAINS having different activity profiles. In (a) to (c), pairs of ASs are shown that contain the same PAINS substructure
(red) but have different activity profiles. For each compound, the number of assays it was tested in, the number of assays in which it was active,
and the corresponding hit rate are reported. For each pair of ASs, assay overlap is quantified. (a) Rhodanines, (b) 3-alkylindoles, (c) Mannich bases.
35644 | RSC Adv., 2017, 7, 35638–35647 This journal is © The Royal Society of Chemistry 2017
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ring in the compounds on the right and, in addition, bound to
two other rings. Thus, the structural context in which the PAINS
substructure was presented in these two ASs was distinct and
one may hypothesize that a more or less constrained structural
environment affects Mannich base reactivity.
In addition to comparing different ASs containing the same
PAINS, it is also informative to analyze individual series with
Fig. 7 Analog series comprising PAINS and non-PAINS. Examples of
‘mixed’ ASs are shown that consist of compounds with and without
PAINS substructures (red). The representation is according to Fig. 5.
PAINS include (a) tertiary anilines, (b) amino imidazoles, and (c)
phenolic Mannich bases.
Fig. 6 Analog series with PAINS having large variations in hit rates.
Exemplary ASs are shown in which compounds display significantly
different hit rates. The representation is according to Fig. 5. (a) Alkyli-
dene thiobarbiturates, (b) quinone derivatives.
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 35638–35647 | 35645
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different activity proles. For example, Fig. 6a shows a series
of alkylidene thiobarbiturates with varying hit rates. Here,
replacement of a 1-methyl-pyrrol with a 3-pyridinmethanamine
group greatly reduced hit rates or completely abolished activity.
In addition, replacing the aromatic (4-uorophenyl)-methyl
substituent with increasingly aliphatic moieties might also
contributed to a loss in activity. Hence, on the basis of these
observations, several experimentally testable hypotheses can be
formulated.
Fig. 6b depicts an AS of 9,10-dihydro-9,10-dioxo-2-
anthracenesulfonamides containing a quinone substructure,
a notorious PAINS4 with one of the highest hit rates overall.
However, in this AS having an unusual ‘green-red’ activity
prole, one of the analogs was found to be consistently inactive
in 430 assays. Compared to a closely related compound with
activity in seven assays, the only modication was a para-to-
ortho repositioning of methyl substituents at the phenyl moiety;
a puzzling observation.
So far, only ASs exclusively consisting of PAINS were
considered. However, series containing analogs with and
without PAINS substructures also revealed interesting rela-
tionships. For example, Fig. 7a shows an ASs with a ‘red-only’
activity prole in which consistently inactive analogs contained
a 1,4-diphenyl-2,6-piperidinedione core. Three of four analogs
had different phenyl derivatives as substituents at the 2,6-
piperidinedione nitrogen. Replacement of these groups with
a N,N-dimethylaniline PAINS substructure also produced
a completely inactive analog, although several likely interfer-
ence mechanisms were proposed for tertiary anilines.34 Thus, in
this case, the 1,4-diphenyl-2,6-piperidinedione core restricted
possible reactivity of different substituents.
Fig. 7b shows an ASs with a ‘green-only’ activity prole
containing different amino imidazole derivatives, only one of
which was a PAINS substructure. However, all analogs were
active in seven to nine assays. Finally, Fig. 7c depicts an AS with
three compounds containing a phenolic Mannich base that
were active in 19 or 25 assays. In a fourth analog, methylation of
the phenolic hydroxyl group of the Mannich base led to
consistent inactivity. The only caveat in interpreting these
results was that the inactive analog was tested in 268 assays,
while the remaining active compounds were tested in more
than 400 or 500 assays (mostly including the 268 assays). Thus,
these differences in assay frequency might inuence hit rates.
Nonetheless, analysis of this series immediately provides the
experimentally testable hypothesis that methylation of the
reactive phenolic hydroxyl might ‘disable’ this PAINS structure.
Many other ASs including PAINS are available to explore the
dependence of assay interference on the structural context in
which PAINS are presented.
Conclusions
In this work, we have systematically extracted ASs with PAINS
substructures from extensively assayed compounds, analyzed
their activity proles, and explored structure–activity relation-
ships. These ASs provided an organization of PAINS according
to varying structural contexts and a reference frame for studying
PAINS actions in different environments. A number of instruc-
tive examples have been identied, providing rst insights into
the structural context dependence of PAINS activities. As a part
of our study, all ASs containing PAINS are made freely available
(in an open access deposition referring to this work) to aid in
theoretical and experimental follow-up investigations to further
explore PAINS characteristics and the inuence of structural
embedding.35
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Conclusions
A first assessment of the structural context dependence of PAINS activities
has been presented. A set of 177 individual PAINS classes were available in a
large number of analog series of extensively tested screening compounds, thereby
providing structural context information of PAINS. Activity profiles of series
were systematically generated based on hit rates of analogs in screening assays.
Depending on the PAINS substructure, analog series showed varying activity
phenotypes. For example, quinones were predominantly found in series with high
hit rates, while derivatives of tertiary anilines and indoles often displayed low
activities or inactivity.
Moreover, analogs or different analogs series containing the same PAINS sub-
structure were compared. Thus, structural modifications were identified that had
significant influence on the hit rates of interference compounds. These included,
among others, methylation of Mannich bases and different aromatic substitution
of unsaturated rhodanines.
In this work, PAINS were organized according to varying structural contexts
and activity profiles. Thereby a reference frame for the exploration of interference
in different structural environments was provided. However, given the complexity
of interference mechanisms and the variety of liable substructures, it remains
difficult to formulate general rules of structural context dependency based on
the study of instructive examples. Hence, in the next chapter we apply machine
learning methods for a systematic classification of PAINS that are highly promis-
cuous from others that are consistently inactive. The analysis of structural features
that favor correct predictions further supports the analysis of structural context
dependence.
59
60
5 Machine Learning Distinguishes
with High Accuracy Between
Pan-Assay Interference Compounds
that are Promiscuous or Represent
Dark Chemical Matter
Introduction
Structural alerts offer a good opportunity to detect potential false-positives
and assay artifacts at an early stage of drug discovery programs. However, assay
interference activities are strongly dependent on experimental conditions and the
structural embedding of chemically liable substructures. Due to this complexity,
it is difficult to predict undesired reactivities sufficiently, as decisions can often
only be made on a case-by-case basis. To address this problem, machine learn-
ing methods were used to distinguish between promiscuous comopounds and
compounds that display consistent inactivity, often referred to as ’dark chemical
matter’ (DCM).151 Based on their representation as ECFP4 and MACCS structural
fingerprints, PAINS were classified using support vector machines, random forest,
and deep neural networks.
In the following chapter, structural features that support correct predictions
are identified and evaluated for their role in the structural dependence of PAINS
activities.
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My main contribution to this work included weighting, mapping, and analysis
of EFCP4 features that favored correct classification by support vector machines.
This study was published as: S. Jasial, E. Gilberg, T. Blaschke, J. Bajorath. Ma-
chine Learning Distinguishes with High Accuracy between Pan-Assay Interference
Compounds that are Promiscuous or Represent Dark Chemical Matter. Journal of
Medicinal Chemistry 2018, 61, 10255–10264.
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Materials and Methods
A subset of 437,257 extensively assayed screening compounds152 from Pub-
Chem BioAssays153 that were tested in both primary assays (percentage of inhibi-
tion from a single dose) and confirmatory assays (dose-response assays yielding
IC50 values) provided the starting point of our analysis. The set of extensively
assayed compounds was screened in silico for PAINS using three publicy available
PAINS filters (RDKit,154 ZINC,155 and CHEMBL156). Filtering identified 270 differ-
ent PAINS substructures present in 27,520 screening compounds. Based on assay
activity profiles of all compounds containing PAINS, two data sets were generated.
The first set consisted of 5233 promiscuous PAINS (termed PROM_PAINS). Com-
pounds were classified as PROM_PAINS if they were tested in at least 100 primary
and varying numbers of confirmatory assays and were active in 10 or more assays.
Additionally, compounds qualified for PROM_PAINS if they were tested in at least
50 confirmatory assays and varying numbers of primary assays and showed activ-
ity in 10 or more assays. The second set consisted of 3059 compounds with PAINS
substructures that were consistently inactive in at least 100 primary and varying
number of confirmatory assays, thus displaying dark chemical matter (DCM)
character (termed DCM_PAINS). DCM_PAINS and PROM_PAINS represented 94
and 192 PAINS substructures, respectively.
Weighting of structural features and their subsequent analysis was based on
a classification model utilizing support vector machines (SVM). In this model,
PROM_PAINS and DCM_PAINS were projected as vectors into a multidimen-
sional feature space, based on their representation as an extended ECFP4 feature
vector. SVMs are used to solve the classification problem by generating a hyper-
plane in feature space that best distinguishes training instances with different
binary class labels (i.e. PROM vs. DCM_PAINS).157 Test compounds were then
classified depending on which side of the separating hyperplane they fell.
The classification model was built for ’balanced’ training sets in which the
numbers of PROM_PAINS and DCM_PAINS were adjusted for shared PAINS
substructures. Thus, 54 individual PAINS substructures were represented by at
least two DCM_PAINS and PROM_PAINS distributed equally and then randomly
divided into training (50%) and test compounds (50%). Ten independent sampling
trials were carried out yielding ten balanced training and test sets. In each trial,
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distinctintersectionsubset
Figure 1: Structural embedding of ECFP4 features. The three structural context cate-
gories are shown by the example of a training set rhodanine derivative (PAINS code:
ene_rhod_A). Mapped features are traced in blue and the PAINS substructure is colored
red. The figure has been adapted from [159].
each training and test set contained approximately 1900 compounds.
A feature weighting method158 was applied to assign different weights to indi-
vidual ECFP4 features that favored correct predictions of the classification model.
Features were ranked according to their preferred presence in either PROM_PAINS
or DCM_PAINS. SMARTS string representations of the top 30 ECFP4 features from
each ranking were used to search for substructures in PAINS utilizing the KNIME
implementation150 of the RDKit substructure filter.154 For a successful match, the
list of atom indices was used to map features to compounds in the test set. De-
pending on their structural embedding, mapped features were assigned to three
structural context categories. As shown in Figure 1, these categories comprised
features (i) representing a subset of a PAINS substructure (subset); (ii) being part
of a PAINS substructure and part of its structural environment (intersection); and
(iii) mapping to a region in a test compound outside of the PAINS substructure
(distinct).
Results and Discussion
In the first part of this study, we examined three different machine learning
algorithms with respect to their ability to distinguish between promiscuous PAINS
and those that were consistently inactive through numerous biological screening
assays. These classification methods included SVM, random forest, and deep neu-
ral networks and were applied using MACCS and ECFP4 structural fingerprints
as molecular representations of PAINS. Independent of the used method, accurate
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Figure 2: Receiver operating characteristic (ROC) curve for a balanced SVM model. A
ROC curve is shown for an individual classification trial distinguishing PROM_PAINS
and DCM_PAINS using SVM on the basis of ECFP4 structural fingerprints. The sensitivity
indicates the proportion of correctly predicted PROM_PAINS and is plotted on the y-axis
(true positive rate). On the x-axis, the 1-Specificity value shows the ratio of DCM_PAINS
predicted as PROM_PAINS (false positive rate). The figure has been adapted from [159].
classification models were obtained for a global data set and a balanced set. To
account for potential substructure bias and data imbalance, the balanced set con-
tained training and test compounds that exclusively originated from shared PAINS
motifs of equally distributed PROM_PAINS and DCM_PAINS. Figure 2 shows a
receiver operating characteristic (ROC) curve for an individual classification trial
using a balanced SVM model on the basis of ECFP4 molecular representations.
Notably, the classification was solely guided by association of structural feature
distributions with the binary class label and did not consider additional param-
eters such as reactivity or activity annotations. Thus, the stable performance of
the balanced model indicated that the applied machine learning methods were
capable of distinguishing between structural contexts of actives and inactives in
which shared PAINS substructure were embedded.
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contribution feature rank
positive 14
pyridinium (active)
unsaturated
ketone (active)
contribution feature rank
positive 10
aniline (active) aniline (active)
Figure 3: Positive ECFP4 feature. Shown are SMARTS representations of ECFP4 fea-
tures from SVM predictions that were highly ranked for PROM_PAINS. In exemplary
PROM_PAINS, mapped features are traced in blue and PAINS substructures are colored
in red. At the top, a N,N-di-substituted aniline ECFP4 feature detected in aniline type
PROM_PAINS (PAINS codes: anil_di_alk_A and anil_di_alk_D) is shown. At the bottom, an
ECFP4 feature covering an unsaturated alkene found in PROM_PAINS is shown. (PAINS
codes: het_pyridinium_A and ene_one_ene). The figure has been adapted from [159].
In the second part of this work, we intended to analyze the structural and
topological patterns that were selected and utilized for correct classification by
machine learning algorithms to expand our knowledge of the structural context
underlying PAINS activities. Given the blackbox character of machine learning
models, we adapted a feature weighting approach developed for SVM158 to explore
determinants of the predictions and calculated cumulative positive and negative
feature weights for all ECFP4 features of test compounds in balanced data sets.
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Then, features were ranked for PROM_PAINS and DCM_PAINS according to
positive and negative weight sums, respectively. For example, a total of 19,668
ECFP4 features were detected for a given balanced test set, of which 2573 and
2527 features had positive and negative weight sums, respectively. On the basis of
this result, 30 top ranked features were identified for each PROM_PAINS (termed
positive features) and DCM_PAINS (negative features) and provided the basis of
the feature analysis.
contribution feature rank
negative 10
pyridine dye (inactive)
unsaturated
rhodanine (inactive)
contribution feature rank
negative 20
azo dye (inactive)
unsaturated
barbituric acid (inactive)
Figure 4: Negative ECFP4 features. Shown are features from SVM predictions that were
highly ranked for DCM_PAINS. Mapped structural features are marked in blue and PAINS
motifs are colored red. On top, an amide pattern found in DCM_PAINS (PAINS codes:
dyes5A and ene_rhod_A) and on bottom the mapping of an aliphatic heterocycle (PAINS
codes: ene_six_het_A and azo_A) is shown. The figure has been adapted from [159].
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Frequent negative features included aliphatic carbon atoms with different de-
grees of hydrogen substitution, cyclic aliphatic ethers, and sp2-hybridized oxygen
atoms of carbonyl and sulfonyl groups. On the other hand, patterns of conjugated
ring systems, chlorine and sulfur atoms, and unsaturated hydrocarbons adjacent to
ring systems were among the preferred positive features. As a result, high-ranked
positive and negative features were found to be composed differently.
Positive features were preferentially associated with reactive moieties, while
negative features were chemically more inert. For example, Figure 3 (top) shows
an N,N-di-substituted aniline motif that is a part of a PAINS substructure and pref-
erentially emerges in PROM_PAINS. Indeed, these aromatic tertiary amines are
present in 23 PAINS substructures25,38,41,48 and thought to interfere with fluoromet-
ric assays by quenching.160 In addition, Figure 3 (bottom) shows a β-unsaturated
alkene bisecting two ring systems, which was also prevalent in PROM_PAINS.
This atom arrangement is a part of a recurrent Michael acceptor motif that occurs
in a variety of PAINS substructures. In contrast, Figure 4 shows examples of highly
ranked negative features representing amide bond and morpholino patterns that
preferably appear outside PAINS substructures and are not associated with known
interference mechanisms.
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feature chemicalreactivity ratio
PROM_PAINS
example
electrophile 3.21
electron 
withdrawing 1.53
quenching 2.48
Figure 5: Prominent features with positive weight. The SMARTS representation of ex-
emplary positive features and their possible chemical reactivity is provided. The ratio of
their frequency of occurrence in PROM_PAINS versus DCM_PAINS is reported (ratio).
For each feature an exemplary compound is shown. The structural feature is traced in blue
and the PAINS substructure is colored in red. The figure has been adapted from [159].
In Figure 5, exemplary features with positive weight in PROM_PAINS are
shown and their possible chemical reactivity is provided. The frequency of occur-
rence of these features in PROM_PAINS was higher than in DCM_PAINS.
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PAINS code PAINS substructure
ene_rhod_A
feature contextcategory example
1
subset
2
subset
3
intersection
4
distinct
5
distinct
Figure 6: Structural context analysis of unsaturated rhodanines. For rhodanines (PAINS
code: ene_rhod_A) positive features are mapped onto exemplary compounds. Mapped
features are traced on a blue background and atoms of the PAINS substructure are colored
red. For each feature, the structural context category is provided, as defined in the text.
The figure has been adapted from [159].
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The analysis showed that calculated ECFP4 features classifying promiscuous
and inactive PAINS often constituted structural patterns related to the potential re-
activity of PROM_PAINS, providing a rationale for successful global classification.
Yet, different activities of compounds belonging to the same PAINS class and their
correct classification could only be rationalized by studying the structural environ-
ment in which the PAINS substructure was incorporated. To address this issue,
top ranked ECFP4 features were mapped onto PROM_PAINS and DCM_PAINS
and categorized with respect to their structural embedding. Accordingly, subset
features were incorporated in PAINS substructures, intersection features were over-
lapping with the PAINS substructure and the remaining structure of a compound,
and distinct features were entirely localized outside PAINS substructures.
Figure 6 shows exemplary positive ECFP4 features belonging to different
categories for unsaturated rhodanines. Five-membered heterocycles such as rho-
danines represent a prominent PAINS class, but have also been considered as
privileged scaffolds in drug discovery.49 Unsaturated rhodanines are prone to
ring opening reactions, metal chelation, and have a strong tendency to react with
nucleophilic thiol groups through a Michael-type addition at the exocyclic dou-
ble bond.161–163 The potential reactivity of the exocyclic double bond towards
biological nucleophiles is a prime example of structural context dependency, as
many compounds containing this substructure elucidate varying activity profiles,
including promiscuous and consistently inactive PAINS. As discussed above, iden-
tification of positive and negative features dit not only put reason on successful
classifications, but their mapping and categorization also provided an insight
into the influence of structural context on predictions. Positive features that were
absent or underrepresented in DCM_PAINS characterizing accurately classified
rhodanine PROM_PAINS are shown in Figure 6. Subset feature 1 and intersection
feature 3 cover a sp2-hybridized exocyclic carbon, the position at which attacks
of reactive nucleophiles, such as thiols, typically occur. Furthermore, intersection
feature 3 underlines the importance of an additional ring system in vicinity of
the Michael acceptor. Consequently, the presence of the aromatic feature 4 in
conjugation with the unsaturated bond favors Michael acceptor activity, which
is supported by further decreasing the electron density of the double bond, for
example, by a chlorine substitution (feature 5).
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PAINS code PAINS substructure
sulfonamide_B
feature contextcategory example
1
subset
2
intersection
3
intersection
Figure 7: Structural context analysis of phenylsulfonamides. For p-
hydroxyarylsulfonamides (PAINS code: sulfonamide_B) positive ECFP4 features
are mapped onto exemplary compounds. Mapped features are traced on a blue
background and atoms of the PAINS substructure are colored in red. For each feature, the
structural context category is given, as defined in the text. The figure has been adapted
from [159].
The structure class of p-hydroxyarylsulfonamides (PAINS code: sulfonamide_B)
typically displays undesired redox and thiol reactivity if they contain a naphtha-
lene core.41,164,165 As shown in Figure 7, the intersection features 2 and 3 mapped
onto correctly predicted PROM_PAINS cover this condition.
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PAINS code PAINS substructure
indol_3yl_alk
feature contextcategory example
1
intersection
2
distinct
3
distinct
Figure 8: Non interpretable feature mapping. For the PAINS class indol_3yl_alk, positive
ECFP4 features are mapped onto exemplary compounds. The structural context categegory
for each feature is provided. ECFP4 features are traced on a blue background, and PAINS
substructures are colored red. The figure has been adapted from [159].
Despite consistent interpretation of feature mappings, positive features mapped
onto test compounds could not always be easily interpreted in chemical terms.
For example, positively weighted features detected for alkylindoles (PAINS code:
indol_3yl_alk) could not be directly associated with the likely interference mecha-
nism of this class, as shown in Figure 8. Here, positive features in PROM_PAINS
displayed conjugated ring systems that were distant to the indoline 3-position
whose tautomer is prone to unwanted Micheal-type reactivity.38
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PAINS code PROM_PAINS DCM_PAINS
ene_five_het_A
ene_cyano_A
Figure 9: Correctly predicted PROM_PAINS and DCM_PAINS. Exemplary
PROM_PAINS and DCM_PAINS are shown for two PAINS classes (PAINS codes:
ene_five_het_A and ene_cyano_A) in absence or presence of mapped ECFP4 features. PAINS
substructures are colored in red and mapped features are traced on a blue background.
The figure has been adapted from [159].
However, we also found that the correct classification by the SVM model could
be directly related to the presence or absence of a positive or negative feature in
structurally similar compounds. Figure 9 shows two exemplary PAINS classes.
In the first example, the conjugated quinolone bicycle adjacent to the exocyclic
double bond of the PAINS substructure (PAINS code: ene_five_het_A) rationalized
the correct prediction of PROM_PAINS. On the contrary, when this feature was
not present and replaced by a secondary amine, another compound was correctly
predicted as a DCM_PAINS. In the second example, reactivity of the PAINS
motif (PAINS code: ene_cyano_A) might depend on the reactivity of the exocyclic
unsaturated carbon, bisecting two carbonitrile moieties. Introducing an electron
donating methoxy substituent is expected to increase electron density of the
conjugated system and thus decrease the likelihood of nucleophilic attacks at this
site. As shown in Figure 9, a methoxy group represented a feature negatively
weighted by the SVM model and its presence supported the correct prediction of
DCM_PAINS.
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Conclusions
In this chapter it has been demonstrated that machine learning algorithms have
the ability to distinguish highly promiscuous from consistently inactive PAINS.
Classification models were applied to balanced data sets in which compounds of
a given PAINS substructure were equally distributed among promiscuous and
inactive compounds. Therefore, it was concluded that machine learning methods
must recognize and utilize differences in topology and structure of differently
active PAINS to ensure accurate classification.
To interpret these models, a feature weighting and mapping method was
applied that indirectly assessed the predictions of support vector machines. A
number of positively weighted ECFP4 features were identified which included
PAINS substructures and reactive moieties that were predominantly found in
promiscuous PAINS. Moreover, the localization of positive and negative features
in correctly classified PAINS allowed further exploration of the structural envi-
ronment of PAINS displaying different activity profiles. For example, electron
withdrawing substituents in the vicinity of reactive Michael acceptors frequently
favored the classification of PAINS as promiscuous.
Nevertheless, it must be taken into account that not all correct or incorrect
predictions can be easily rationalized by analyzing structural features and that
the performance of machine learning models generally depends on calculation
conditions. However, as shown in the previous studies, key for an accurate assess-
ment of assay interference is the large scale exploration of the complex interplay
between structural features that cause undesired chemical reactivities. Therefore,
the use of classification models that take available structural context information
into account provides a valuable addition to the use of PAINS substructure filters
and knowledge-based assessment of chemical liabilities.
In the next chapter, the SAR analysis of PAINS is complemented by a data-
driven assessment of assay promiscuity. Therefore, a systematic analysis of hit
rates and structural relationships of extensively assayed screening compounds
was carried out.
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6 Towards a Systematic Assessment
of Assay Interference: Identification of
Extensively Tested Compounds with
High Assay Promiscuity
Introduction
In the previous chapter it has been demonstrated that distinguishing potential
liabilities from true multitarget activities of promiscuous screening compounds
remains a difficult task. Especially the sole use of substructure filters does not do
justice to the multifaceted picture of assay interference. For many PAINS classes,
interference properties between derivatives may differ according to structural
and experimental contexts. Moreover, as discussed in the first chapter, publicly
available structural alerts do not comprehensively cover interference mechanisms.
This chapter addresses these challenges through a data-driven analysis of
promiscuous compounds, without reducing available compounds through the
prior use of structural filters. Taking structural context into account, MMSs of ex-
tensively tested screening compounds are generated and characterized according
to their series hit rates and experimental assay overlap. Data sets are made freely
available for follow-up investigations.
My main contribution to this work was the statistic analysis of extensively
tested screening compounds and generation and classification of MMS.
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Introduction
Compounds with false-positive signals in biological assays 
cause substantial problems for biological screening and medici-
nal chemistry1. Assay artifacts often remain undetected or are 
unveiled only at later stages of compound development efforts, 
leading to substantial loss of time and resources. Moreover, once 
published, artificial activities spread through the scientific litera-
ture and potentially cause even more harm by inspiring follow-up 
investigations that are doomed to fail. Known assay interference 
compounds include colloidal aggregators2–7 and many other com-
pound classes that can react in different ways or are fluorescent 
under assay conditions6–15. Systematic efforts to identify inter-
ference compounds include the compilation of aggregators2–4 
and pan-assay interference compounds (PAINS)8,9. The latter 
comprise a set of 480 classes of compounds originally identi-
fied in AlphaScreen assays8. PAINS are typically contained as 
substructures in larger compounds. However, the assessment and 
prediction of assay interference is far from being a trivial exer-
cise. For example, analysis of screening data from PubChem16 
has revealed that many compounds containing PAINS, includ-
ing most reactive chemical entities, have very different hit rates 
or might be consistently inactive17,18. Moreover, analogs or dif-
ferent series of analogs containing the same PAINS substruc-
ture often have distinct activity profiles and are active against 
different targets19. Thus, interference characteristics of related 
compounds frequently differ and a substructure with interference 
potential does not necessarily give rise to false-positive assay 
signals. To further complicate matters, promiscuous compounds 
may also have true multi-target activities20 that are relevant for 
polypharmacology20–22. Moreover, even highly promiscuous 
screening hits include molecules with no apparent liabilities, in 
addition to obvious interference compounds12.
Without doubt, judging assay interference and candidate com-
pounds requires profound chemical knowledge and experience. 
It is equally relevant, however, to strive for a data-driven assess-
ment of promiscuity by exploring compound activity data on a 
large scale20, aiming to identify compounds with interference 
potential for further analysis. Previously, we have determined 
that increasing assay frequency of pairs of structural ana-
logs did not correlate with differences in promiscuity23. The 
current analysis was focused on hit rates of individual com-
pounds that were extensively assayed to identify the overall 
most active chemical entities. Therefore, we have carried out a 
statistical analysis of hit rates of compounds that were exten-
sively tested in screening assays. These compounds were evalu-
ated in on average 411 assays (with a median value of 437 
assays per compound). A special feature of this study has been 
its focus on pairs or larger series of analogs, rather than single 
compounds, which provides additional confidence criteria for 
activity assessment and further increases the information con-
tent of activity data analysis. Many series of analogs with much 
higher than typically observed hit rates and largely consistent 
activity profiles across many different assays were identified. 
This collection of series provides a basis for further investigat-
ing compounds with interference potential or true multi-target 
activities.
Methods
Compounds
From the PubChem BioAssay database16, 437,257 com-
pounds were pre-selected that were tested in both primary and 
confirmatory assays, representing extensively assayed screening 
compounds23. Approximately 95% of these compounds were 
evaluated in more than 50 primary and/or confirmatory assays23. 
Primary PubChem assays report compound activity (e.g., 
percentage activity) for a single dose, while confirmatory assays 
are dose-response assays yielding titration curves and IC50 values. 
Our current analysis focused on primary assays, for which much 
larger data volumes were available than for confirmatory assay. 
Primary assays also included assays for which no target was 
specified (such as cell-based assays). In addition to larger volumes, 
primary assays are more prone to false-positives than confirma-
tory assays, thus providing an upper-level estimate of compound 
promiscuity consistent with the goals of our analysis. Assignments 
of active compounds were taken from each individual assay as 
reported. Screening parameters such as compound concentration 
and activity criteria were assay-dependent. For pre-selected com-
pounds, hit rate statistics were determined.
Matched molecular pairs and series
A matched molecular pair (MMP) is a pair of compounds that are 
only distinguished by a chemical change at a single site24, termed 
a chemical transformation25. As an extension of the MMP concept, 
a matched molecular series (MMS) was defined as the union of all 
MMP compounds that are only distinguished by chemical modifi-
cations at a given site26. Accordingly, an MMS represents a series of 
analogs sharing a single substitution site. To generate MMPs, exo-
cyclic single bonds in screening compounds were systematically 
fragmented25 following retrosynthetic fragmentation rules27, 
yielding so-called RECAP-MMPs28. These MMPs were sub-
ject to transformation size restrictions in order to limit chemical 
changes to modifications typically observed in series of analogs29. 
An MMS was designated as redundant if it was a subset of a 
larger MMS or if there was another MMS representing the 
same series of analogs but having a larger MMP core. For screen-
ing compounds with high hit rates, non-redundant MMS were 
systematically determined.
MMS parameters
For each MMS, three parameters were calculated. First, the MMS 
hit rate (HR) was obtained from the union of all assays (i.e., the 
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number of unique assays in which one or more analogs were 
tested in) and assays with activity signals (active assays, i.e., the 
number of unique assays in which one or more analogs were 
found to be active). Second, assay overlap was determined as the 
proportion of assays in which all MMS compounds were tested 
in (shared assays, i.e., the intersection of assays) relative to the 
union of assays. Third, from assay overlap, assays with 
inconsistent activity were calculated as the proportion of shared 
assays in which different MMS compounds were active or 
inactive.
All calculations were carried out using in-house Java scripts and 
KNIME30 protocols with the aid of the OpenEye31 chemistry 
toolkit.
Results and discussion
Study design
A statistical analysis of hit rates of extensively tested screen-
ing compounds is presented taking assay frequency into account. 
On the basis of the hit rate distribution, ranges of unusually 
high hit rates were determined. Since the majority of compounds 
that were active in primary assays were also active in confirma-
tory assays, a high level of consistency in the assignments of 
active compounds was observed. From compounds with high hit 
rates, analog series with single substitution sites (MMSs), i.e., 
“minimal” chemical modifications within series, were system-
atically extracted, which provided structural context information 
and hit rate controls for closely related compounds. For MMSs, 
different parameters were calculated, making it possible to 
compare and prioritize these series. The collection of MMSs with 
high hit rates provides a basis for investigating assay interference 
candidates, as well as chemical entities with potential multi-target 
activities.
Figure 1. Assay frequency distribution. The frequency distribution of primary assays is shown in a boxplot format for 437,257 pre-selected 
PubChem compounds and a subset of 327,532 compounds. The plot gives the smallest number of primary assays (lower whisker), first 
quartile (lower boundary of the box), median value (thick line), third quartile (upper boundary of the box), and largest number of assays 
(upper whisker). Outliers are not displayed. The dashed blue line indicates the selection criterion for the compound subset (i.e., tested in 
more than 257 primary assays).
Source compounds and assay distribution
Figure 1 (boxplot on the left) shows the global distribution 
of primary assays for 437,257 extensively tested PubChem 
compounds, with a median value of 347 assays per compound. 
From these, a subset of 327,532 compounds was selected that 
were tested in more than 257 primary assays, corresponding to the 
lower quartile boundary of the global distribution. For this subset, 
the assay distribution was separately monitored (Figure 1, boxplot 
on the right), yielding a median of 426 (and a maximum of 626) 
assays per compound. Hence, half of these compounds were tested 
in more than 426 primary assays.
Hit rate distribution
For 327,532 compounds tested in more than 257 assays, hit 
rates were determined. The distribution is reported in Figure 2 
(boxplot on the left), resulting in a median hit rate of 0.4%. The 
lower quartile boundary and lower whisker of the boxplot were 
identical and represented consistently inactive compounds, which 
were not of interest for our current analysis. On the basis of 
the distribution, the interval of “bulk hit rates” (b_hr) for these 
extensively assayed PubChem compounds was defined as 
0% < b_hr ≤ 1.0%, covering the lower quartile, median, and 
upper quartile (and hence the “bulk” of the distribution). There 
were 80,495 compounds with hit rates ≥ 1.0%. The hit rate 
distribution of this compound subset is shown in Figure 2 
(middle), yielding a median of 1.8%. This value was set as the 
hit rate threshold for most active screening compounds. The 
threshold was exceeded by 41,609 compounds, representing 
12.7% of the initial compound pool. The hit rate distribution of 
these compounds is reported in Figure 2 (right), resulting in a 
median of 2.9%. We determined that 93.1% of the compounds with 
hit rates greater than 1.8% in primary assays were also active in 
confirmatory assays (yielding IC50 values). Hence, their activity 
was not confined to primary assays.
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Figure 2. Hit rate distribution. For three different subsets of PubChem compounds, hit rate distributions are shown in boxplots according to 
Figure 1. The subsets are characterized by increasing hit rates (marked by dashed blue lines).
Compound series and parameters
From the 41,609 compounds with highest hit rates, MMSs 
were systematically extracted on the basis of RECAP-MMPs. 
After removal of redundant MMSs (see Methods), 6941 unique 
MMSs were obtained comprising 14,646 compounds, which 
represented our final hit rate- and series-based selection set. 
Table 1 reports the size distribution of the MMSs, ranging from 
two to 17 analogs per series. With 6111 instances, compound 
pairs and triplets dominated the distribution, but more than 
800 larger MMSs were also obtained. Increasing size of MMSs 
may lead to higher hit rates, variations in assay overlap, and 
more assays with inconsistent activity. As further discussed 
below, compound pairs and triplets already provide informative 
controls for activity analysis and enable a more confident assess-
ment compared to the analysis of individual compounds. This 
was a major motivation for focusing the analysis on MMSs.
Figure 3a illustrates the derivation of three parameters for the 
characterization and comparison of MMSs (rationalized in the 
Methods section). The cumulative MMS hit rate is a direct 
measure for the activity of a series. In addition, assay overlap 
represents a confidence criterion for MMS assessment, i.e., large 
assay overlap of compounds comprising a series assigns high 
confidence to hit rate comparisons. By contrast, the proportion 
of assays with inconsistent activity should best be minimal to 
draw firm conclusions. Figure 3b reports the distribution of these 
three parameters for the 6941 MMSs. Assay overlap (upper left 
plot) and MMS hit rates (lower left) were generally high, with 
median values of 79.3% and 5.8%, respectively. By contrast, the 
proportion of inconsistent assays (upper right) was overall low, 
with a median of only 3.7%. Thus, the distributions of MMS 
parameters indicated that the set of MMSs was suitable for 
the analysis of series-based hit rates and hit rate comparison of 
compounds comprising individual MMSs. We note that MMSs 
can be ranked in the order of decreasing assay overlap and 
MMS hit rates and increasing inconsistent assays and prioritized, 
for example, on the basis of rank fusion calculations.
Table 1. Size distribution 
of matched molecular 
series (MMSs). The 
distribution of 6941 
frequently active MMSs 
(#MMSs) over increasing 
numbers of compounds 
(#CPDs) is reported.
#CPDs #MMSs
2 4965
3 1156
4 435
5 190
6 70
7 48
8 22
9 21
10 11
11 12
12 3
13 4
14 2
15 1
17 1
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Figure 3. Characterization of matched molecular series (MMSs). (a) An exemplary MMS comprising three analogs is shown. The MMS core 
and varying substituents are colored in black and orange, respectively. For each compound, the number of assays it was tested and active in 
is reported, respectively. Furthermore, the assay union, intersection, and MMS hit rate (purple) are given. From these data, the assay overlap 
(green) of MMS analogs was determined as well as the proportion of assays with consistent activity, inactivity, and inconsistent activity (blue). 
(b) Boxplots are shown reporting the distribution of assay overlap, assays with inconsistent activity as well as assay- or target-based MMS hit 
rates for PubChem compounds with greater than 1.8% hit rate.
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Target distribution in primary assays
Our analysis was intentionally focused on hit rates over assays 
(i.e., assay promiscuity) to take as many activity readouts as 
possible into account. Therefore, as a control, assay- and target-
based hit rates were also compared. Compounds forming the 
6941 MMS were evaluated in a total of 1213 assays. For 255 of 
these assays, no individual target was specified. The remaining 
958 assays covered 426 different targets. Figure 3b reports the 
distributions of MMS hit rates over assays (lower left plot) and 
targets (lower right). The distributions were overall similar, 
with median values of assay- and target-based hit rates of 5.8% 
and 4.9%, respectively. Hence, despite the presence of multiple 
assays for a subset of targets, assay-based hit rates were only 
slightly higher than target-based rates, indicating that corre-
sponding conclusions would be drawn from the analysis of these 
distributions.
Known interference candidates
The computational aggregation advisor4 and compound strings 
taken from PAINS filters32,33 (http://www.rdkit.org) were used 
to search the MMSs for known assay interference candidates. 
The 14,646 MMS compounds contained 783 aggregators (on the 
basis of 100% similarity) and 2381 compounds with PAINS sub-
structures. There were 611 MMSs with one or more aggregators, 
1139 MMSs with one or more PAINS, and 126 MMSs including 
aggregators and PAINS. However, 5065 MMSs with high hit rates 
did not contain known compounds with aggregation potential or 
PAINS substructures. Thus, the MMSs provide a large source of 
analogs for the exploration of other interference candidates, as 
well as compounds with true multi-assay/target activities.
Exemplary series
Figure 4 shows exemplary compound pairs and triplets with high 
assay promiscuity. The two analogs in Figure 4a were tested in 
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Figure 4. Exemplary matched molecular series (MMSs). (a–d) Four exemplary MMSs (core, black; substituents, orange) are shown and 
the MMS hit rate, assay overlap, and proportion of assays with inconsistent activity are reported. In addition, for each individual analog, its 
assay frequency and hit rate are provided.
more than 380 assays with 93.5% assay overlap and only 1.6% 
inconsistent assays, yielding comparable hit rates of 2.8% and 
3.2%, respectively, resulting in an MMS hit rate of 4.5%. These ana-
logs contained a classical PAINS substructure (ene_rhodanine)8,9. 
Furthermore, compounds in Figure 4b were analogs of a 
molecule with aggregation potential4. They were tested in more 
than 300 and 400 assays, respectively, yielding a relatively 
low assay overlap of 59%, and had hit rates of 2.2% and 2.6%, 
respectively, resulting in a low MMS hit rate of 2.9%. Thus, these 
analogs were far from being consistently active, as one might 
assume for strong aggregators. In Figure 4c, a pair of thieno[2,3-
d]pyrimidine-2-acetic acid ethyl ester analogs is shown that 
were tested in 442 assays with large overlap. These compounds 
had high hit rates of 5.9% and 7.9%, respectively, resulting in 
a high MMS hit rate of 9.8%. Moreover, Figure 4d shows a 
triplet of sulfonylpyrimidines that were tested in 357–361 assays 
with 89.7% overlap, having very high hit rates of 8.7% (one 
analog) and more than 13% (two analogs). The analogs in 
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Figure 4c and Figure 4d have previously not been classified 
as interference candidates. The interference potential of sulfo-
nylpyrimidines was assessed via a SciFinder substructure search 
for 2-[(phenylmethyl)sulfonyl]-pyrimidine. This substructure 
appeared in more than 100 publications related to biological 
studies and more than 1000 chemical reactions. Although the 
potential of sulfonylpyrimidines to undergo nucleophilic aro-
matic substitutions in organic synthesis is well established in 
the literature34,35, reactivities under assay conditions remain to 
be confirmed experimentally. Compounds forming each of the 
MMSs in Figure 4 displayed consistent hit rate characteristics, 
hence assigning confidence to their observed activity phenotype. 
Taken together, these examples of analog pairs and triplets 
(i.e., minimally sized MMSs) are indicative of the potential of 
well characterized MMSs for follow-up investigations focusing on 
assay interference and multi-target activities.
Conclusions
Herein, a detailed analysis of hit rates of nearly 440,000 
extensively assayed screening compounds has been presented. 
On the basis of hit rate distributions, 12.7% of the compounds 
with highest hit rates were selected. From these compounds, 
analog series with single substitution sites were systemati-
cally extracted to complement hit rate statistics with the assess-
ment of structural relationships between active compounds. 
A total of 6941 unique MMSs were obtained comprising 
14,646 compounds. These MMSs were characterized using 
different parameters prioritizing high-confidence series for activ-
ity analysis. A major goal of our study has been the data-driven 
generation of a pool of analog series for the evaluation of assay 
interference potential and multi-target activities. More than 5000 
MMSs did not contain known interference candidates, provid-
ing an opportunity to evaluate compounds with interference 
potential on a large scale. In the next step, analog series will be 
evaluated from a medicinal chemistry perspective to complement 
and further extend statistical considerations. Annotated series 
and associated assay/target information will then be made freely 
available. The statistics and selection steps reported herein also 
make it possible to regenerate compound subsets at different hit 
rate levels and subject them to further analysis. In addition, large 
numbers of compounds with high hit rates that were not part of 
MMSs are also available. For reasons discussed, our preferred 
approach is taking compound series information into account when 
judging assay promiscuity.
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Conclusions
A data set of MMSs for the systematic assessment of assay interference and
multitarget activities was generated. Based on compounds that showed highest
activity in primary biological screening assays, 6941 unique analog series were
systematically extracted that comprised 14,646 compounds. To ensure statisti-
cally sound and chemically meaningful results, series hit rates, assay overlap,
and inconsistent experimental activities between analogs were considered for
the prioritization of MMSs. Data sets were made freely available for follow-up
investigations. Notably, in the generation of MMSs, PAINS alerts were omitted.
Thus, by circumventing previously discussed shortcomings of PAINS filters, a
solely data-driven assessment of assay interference and multitarget activities was
made possible.
The provision of a dataset containing exceptionally promiscuous compounds
and series completed the analysis of assay interference and multitarget activity
based on biological screening data. To provide confirmatory evidence for true mul-
titarget activity that is not caused by chemical interference, a structure-based ap-
proach is applied in the next chapter. Based on structurally confirmed promiscuity,
template structures for multitarget and multifamily ligand design are generated.
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7 X-ray-Structure-Based
Identification of Compounds with
Activity Against Targets from
Different Families and Generation of
Templates for Multitarget Ligand
Design
Introduction
The interpretation of compound promiscuity on the basis of assay data is
a challenging task considering the difficulty of discriminating artificial results
from real multitarget activities. One way to receive confirmatory evidence for
true multitarget binding events is provided by the analysis of X-ray structures of
ligand-target complexes containing promiscuous small molecules.
In this chapter, crystallographic ligands are identified that form multiple com-
plexes with distantly or unrelated targets. For these multifamily ligands, analogs
and additional target annotations are systematically explored in the medicinal
chemistry literature. From analog series of multifamily ligands, molecular scaffolds
are derived to provide references for the design of multitarget ligands.
My contribution to this work was the identification and analysis of crystallo-
graphic multifamily ligands and the generation of analog series based scaffolds.
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Reprinted with permission from ‘E. Gilberg, D. Stumpfe, J. Bajorath. X-ray-Structure-
Based Identification of Compounds with Activity against Targets from Different
Families and Generation of Templates for Multitarget Ligand Design. ACS Omega
2018, 3, 106–111’. Copyright 2018 American Chemical Society
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X‑ray-Structure-Based Identification of Compounds with Activity
against Targets from Different Families and Generation of Templates
for Multitarget Ligand Design
Erik Gilberg,†,‡ Dagmar Stumpfe,† and Jürgen Bajorath*,†
†Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische
Friedrich-Wilhelms-Universitaẗ, Dahlmannstr. 2, D-53113 Bonn, Germany
‡Pharmaceutical Institute, Rheinische Friedrich-Wilhelms-Universitaẗ, An der Immenburg 4, D-53121 Bonn, Germany
ABSTRACT: Compounds with multitarget activity (promis-
cuity) are increasingly sought in drug discovery. However,
promiscuous compounds are often viewed controversially in
light of potential assay artifacts that may give rise to false-
positive activity annotations. We have reasoned that the
strongest evidence for true multitarget activity of small
molecules would be provided by experimentally determined
structures of ligand−target complexes. Therefore, we have
carried out a systematic search of currently available X-ray
structures for compounds forming complexes with different
targets. Rather unexpectedly, 1418 such crystallographic
ligands were identified, including 702 that formed complexes
with targets from different protein families (multifamily ligands). About half of these multifamily ligands originated from the
medicinal chemistry literature, making it possible to consider additional target annotations and search for analogues. From 168
distinct series of analogues containing one or more multifamily ligands, 133 unique analogue-series-based scaffolds were isolated
that can serve as templates for the design of new compounds with multitarget activity. As a part of our study, all of the
multifamily ligands we have identified and the analogue-series-based scaffolds are made freely available.
1. INTRODUCTION
Over the past decade, the interest in small molecules with
multitarget activity has been steadily on the rise,1−3 especially in
the context of polypharmacology.4−7 This concept refers to
increasing evidence that the efficacy of drugs frequently
depends on engagement of multiple therapeutic targets.4−7
Accordingly, the molecular foundation of polypharmacology,
which also includes undesired side effects, is provided by
specific interactions of compounds with multiple targets.8
However, while multitarget drug discovery is given prime
consideration in therapeutic areas such as neurodegenerative
diseases3 and oncology,9 compound promiscuity per se is often
viewed controversially.8 This is the case because it is generally
difficult to draw the line between true multitarget activity of
small molecules8 and aggregation effects or potential reactivity
under assay conditions,10−13 which may or may not14,15 lead to
artifacts and false-positive assay signals.13,16,17 Hence, differ-
entiating between multitarget activity and assay interference has
become a major task in biological screening and medicinal
chemistry.17 In addition to their drug discovery relevance, small
molecules with true multitarget activity are also of high interest
for basic research in order to explore why and how such
chemical entities are capable of forming specific interactions
with multiple targets, especially if these targets are only
distantly related or unrelated and have different functions.
We have been interested in identifying compounds that are
active against target proteins from different families. In light of
potential caveats associated with promiscuity analysis (vide
supra), we have reasoned that particularly strong evidence and
support for multitarget activity would be provided by structural
data confirming that compounds are indeed bound to active
sites of different target proteins. Therefore, we have carried out
a systematic search for X-ray structures of ligands bound to
multiple target proteins from different families. This search was
complemented by identifying and analyzing series of analogues
involving such ligands, thereby bridging between structural
biology and medicinal chemistry.
2. RESULTS AND DISCUSSION
2.1. Crystallographic Ligands. From 102 625 entries in
the RCSB Protein Data Bank (PDB),18 23 580 crystallographic
ligands were extracted, which included 11 039 organic
compounds with a molecular weight of at least 300 Da and
unique structures. This subset of PDB ligands provided the
basis for our analysis. The complete selection protocol is
summarized in Figure 1.
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2.2. Multitarget and Multifamily Ligands. The selected
PDB ligands were found to contain 1418 compounds from X-
ray structures of complexes with at least two different target
proteins (i.e., multitarget ligands; Figure 1). We then
determined that these multitarget ligands contained a subset
of 702 compounds whose crystallographic targets originated
from different families (i.e., multifamily ligands; Figure 1). For
this subset, the median value was three targets per ligand.
Multifamily ligands were most interesting to us because their
structurally confirmed targets were only distantly related (if not
unrelated). Targets of multifamily ligands included 488 human
proteins, which were distributed across different families as
shown in Figure 2. The majority of targets were enzymes.
Among these, transferases were prevalent. This observation can
be explained by considering that the composition of the PDB is
biased toward targets that are straightforward to crystallize
(such as many cytoplasmic enzymes). Consequently, some
major classes of pharmaceutical targets such as G-protein-
coupled receptors and other membrane proteins continue to be
under-represented in the PDB. It is possible to compensate this
inherent target bias in part by mapping of multifamily ligands
from the PDB to ChEMBL and searching for additional target
annotations of these ligands and available structural analogues
from medicinal chemistry, as further discussed below.
2.3. Exemplary Ligands and X-ray Structures. Figure 3
shows X-ray structures of ligands in complex with targets from
different families. Comparison of X-ray structures of the same
ligand in complex with different targets frequently revealed
differences in binding modes. For instance, the phenothiazine
derivative thioridazine shown in Figure 3a was found in five X-
ray complexes with four targets from four different families. As
an exemplary comparison, the binding mode of thioridazine
observed in mucosa-associated lymphoid tissue lymphoma
translocation protein 1 (MALT1),19 a cysteine protease, clearly
differs from the one in aldehyde oxidase,20 an unrelated
enzyme. While the tricyclic ring system of thioridazine is
located in a hydrophobic pocket of MALT1, it is partially
solvent-exposed in the X-ray complex with aldehyde oxidase. In
addition, the positively charged N-methylpiperidinyl moiety
forms charge-assisted hydrogen bonds with Glu397 of MALT1,
whereas the tertiary amine of the ligand forms backbone
interactions with the carbonyl oxygen of Arg1064 in the active
site of aldehyde oxidase.
Figure 3b shows an example of an inverted ligand binding
mode in two different active sites. The flavonoid myricetin was
found in seven complex structures involving six targets from six
different families. It displays opposite head-to-tail orientations
when bound to human pancreas amylase21 and the ATP-
binding site of PIM1 kinase.22
Figure 1. Compound selection. The protocol applied to select
crystallographic ligands, multitarget and multifamily ligands, and
analogues from medicinal chemistry is summarized.
Figure 2. Distribution of human targets of multifamily ligands. The pie chart on the left reports the distribution of human targets from complex X-
ray structures with multifamily ligands. For enzymes, the distribution of catalytic functions is shown in the pie chart on the right.
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Binding modes can also be compared for multifamily ligands
when interactions with different targets lead to desired or
undesired functional effects. An example is shown in Figure 3c,
where the thyroid hormone thyroxine (T4) is bound to the IIa
subdomain of human serum albumin23 or the ligand binding
domain of thyroxine thyroid hormone receptor beta (TR), its
natural receptor.24 Binding to serum albumin causes hyper-
thyroxinemia.23 Notably, T4 reaches deep into the TR binding
pocket, where it interacts with three arginine residues via
charge-assisted hydrogen bonds. In addition, the iodine atoms
of T4 are accommodated in small subsites mostly formed by
the side chains of Phe459 and Phe455. By contrast, T4 binds to
human serum albumin in a surface-directed manner and
predominantly interacts with residues that are partially
solvent-exposed.
2.4. Multifamily Ligands from Medicinal Chemistry. A
subset of 355 of the 702 multifamily ligands were detected in
the ChEMBL database,25 the major public repository of
compounds and activity data from the medicinal chemistry
literature. For these ligands, ChEMBL target annotations from
high-confidence direct binding/inhibition assays were collected.
Taking these additional annotations into account represented
an expansion into medicinal chemistry target space and
increased the median value from three PDB (vide supra) to
17 unique PDB/ChEMBL targets per multifamily ligand. Thus,
crystallographic multifamily ligands were generally promiscuous
on the basis of medicinal chemistry data. Although it cannot be
excluded that some target annotations from assays might be
false positives, the availability of multiple X-ray structures of
these ligands in complex with different targets lends credence
to their promiscuous nature, strongly suggesting their relevance
for the study of multitarget activity and polypharmacology.
2.5. Analogues of Multifamily Ligands. For the 355
multifamily ligands available in ChEMBL, a systematic search
for analogue series (ASs) was carried out. For 243 of these
ligands, analogues were detected, yielding 168 unique ASs. Each
AS consisted of at least one X-ray ligand and varying numbers
of noncrystallographic analogues from ChEMBL. An exemplary
AS is depicted in Figure 4. This AS contains an X-ray ligand
and several ChEMBL compounds with multitarget annotations,
providing corroborating evidence for the promiscuity of the
multifamily ligand from the PDB.
2.6. Scaffolds and Design Templates. From ASs
containing multifamily ligands, analogue series-based (ASB)
scaffolds26,27 were derived. By design, ASB scaffolds take
retrosynthetic criteria into account and capture chemical
information on compound series, including the conserved
substructure and substitution sites where analogues are
distinguished.26,27 For 133 of the 168 ASs with multifamily
ligands ASB scaffolds could be derived. Exemplary scaffolds are
shown in Figure 5. Since ASs were associated with multiple
targets, further extending the set of PDB targets of multifamily
ligands, the corresponding ASB scaffolds also represent
templates for the design of compounds with different
multitarget activities. On the basis of each scaffold, different
target combinations can be explored. The ASB scaffolds also
make it possible to differentiate between template structures
with different degrees of promiscuity. For example, scaffolds
from highly promiscuous analogue series, as shown in Figure 5,
might be deprioritized as template structures for the design of
compounds with desired activity against a few targets, even if
these targets are contained in the scaffold-associated target
profiles. Instead, scaffolds from other less promiscuous series
with desired targets might be considered. Furthermore, for ASB
scaffolds with target combinations of interest, it is advisible to
inspect the target annotations of individual analogues to
Figure 3. Multifamily ligands and X-ray structures. In (a−c),
exemplary ligands and X-ray structures of their complexes with targets
from different families are shown. For each ligand, the total number of
complex X-ray structures, the number of PDB targets, and the number
of families from which these targets originated are reported. In the X-
ray structures, bound ligands are shown in stick representation with
standard atom coloring.
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rationalize the series-based target profile in more detail.
Analogues can be easily obtained by substructure searching
using ASB scaffolds.
2.7. Conclusions. We have systematically searched for
crystallographic ligands bound to multiple targets from different
families. Such X-ray data were thought to provide firm evidence
for true multitarget activity of compounds. An unexpectedly
large number of qualifying ligands (702) were identified that
covered targets from a variety of families. Approximately half of
these ligands originated from the medicinal chemistry literature,
which yielded additional target annotations. Moreover, a total
of 168 distinct series of analogues that contained X-ray ligands
were identified. From these, 133 analogue-series-based scaffolds
were extracted that captured chemical and target information
on individual series. Crystallographic multifamily ligands
represent a large, high-confidence knowledge base for multi-
target activity. Scaffolds derived from ASs containing such
ligands can be considered as templates for compound design.
Therefore, multifamily ligands, scaffolds, and associated target
information are made freely available as a part of this study. We
also note that a variety of computational methods are available
to predict targets of test compounds. The uncertainties
associated with target predictions go much beyond exper-
imental uncertainties associated with compound data. However,
searching for compounds with true multitarget activities is
difficult on the basis of experimental activity data, taking assay-
Figure 4. Analogue series. Shown is an exemplary AS including a multifamily ligand (blue core). For the crystallographic ligand, the number of PDB
targets, the number of targets reported in ChEMBL, and the number of unique targets are given. For each ChEMBL analogue, the number of targets
from ChEMBL is provided. In each case, the corresponding number of target families is given in parentheses. ChEMBL analogues have no PDB
target annotations. Substituents that distinguish analogues are colored red.
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dependent activity readouts and potential artifacts into account.
For these reasons, X-ray structures of ligand−target complexes
provided the initial focal point of our analysis and were
complemented by taking medicinal chemistry data into
account. By contrast, possible computational predictions were
deliberately avoided, given the motivation and scope of our
analysis.
3. MATERIALS AND METHODS
All calculations were carried out using in-house Perl and
Python scripts with the aid of the OpenEye chemistry toolkit,28
KNIME protocols,29 and RStudio.30 X-ray structures were
graphically analyzed using the Molecular Operating Environ-
ment.31
3.1. Ligands from X-ray Structures. X-ray structures and
associated compound data were extracted from the Ligand
Expo section32 of the PDB.18 Salts and other buffer
components were removed, and ligands with a molecular
weight of at least 300 Da yielding unique aromatic nonstereo
SMILES33 representations were retained. Application of the
molecular weight cutoff ensured that small organic components
and fragments were excluded from further consideration. All of
the selected complex X-ray structures were visually inspected.
3.2. Compounds and Activity Data. From ChEMBL
(release 23)25 a total of 853 533 unique compounds were
extracted for which activity data from direct binding/inhibition
assays (target relationship type “D”) were available.
3.3. Target Family Distribution. For crystallographic
targets of human origin, family assignments were obtained by
combining the classification schemes of UniProt34 and
ChEMBL. In addition, known targets of all of the selected
ChEMBL compounds were determined on the basis of unique
UniProt identifiers.
3.4. Analogue Series and Scaffolds. From combined
PDB and CHEMBL compounds, ASs were systematically
extracted using a recently developed algorithm35 utilizing the
matched molecular pair (MMP) formalism.36 An MMP is
defined as a pair of compounds that are distinguished only by a
structural change at a single site,36 often termed a chemical
transformation.37 To generate MMPs, compounds were
systematically fragmented37 according to retrosynthetic
rules,38 yielding RECAP-MMPs.39 From ASs, recently intro-
duced ASB scaffolds26,27 were extracted, which capture the
conserved substructure of a series and all substitution sites.
3.5. Data Deposition. All of the multifamily ligands have
been made available, together with their crystallographic
targets, PDB identifiers, and total numbers of targets, including
annotations from ChEMBL (if available). In addition, all of the
ASB scaffolds derived from ASs containing multifamily ligands
are provided. The collection of ligands and scaffolds is freely
available in a deposition on the Zenodo open access platform.40
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Conclusions
Templates for a polypharmacologically oriented ligand design based on com-
pounds with structurally confirmed multifamily activities were presented. 702
ligands were demonstrated to interact with various targets from different families.
The target space of these ligands was extended by considering target annotations
from high-confidence data of binding and inhibition assays. For 168 multifamily
ligands, ASs were generated by considering structural analogs that were found
in the medicinal chemistry literature. From these series, 133 ASB scaffolds were
isolated.
This study provides a starting point for the use of crystallographic data to
design compounds that can be used for polypharmacology. In this context, it
would be of interest to better understand the molecular basis for true multitarget
activity. In the last chapter, the concept of ligand promiscuity was further analyzed
on the basis of experimental structures to rationalize and compare multifamily
interactions in detail.
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8 Promiscuous Ligands from
Experimentally Determined
Structures, Binding Conformations,
and Protein Family Dependent
Interaction Hotspots
Introduction
True multitarget activity provides the basis for polypharmacology and is of
increasing relevance for drug discovery. However, promiscuity as the molecular
basis of polypharmacology requires careful consideration. In light of the complex
nature of polypharmacology, rational design of multitarget ligands is a challenging
task. Although structural data are limited compared to assay data, the investigation
of promiscuous ligands based on crystallographic complexes provides a major
advantage because these binding events are confirmed at the molecular level and
can be explored as such.
In the following, binding modes and characteristics of multifamily ligands are
systematically explored to understand ligand promiscuity across different target
families. Molecular properties of promiscuous ligands are determined and com-
pared to other PDB compounds. Moreover, binding conformations of multifamily
ligands are analyzed and family dependent interaction hotspots are identified.
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ABSTRACT: Compound promiscuity is often attributed to
nonspecific binding or assay artifacts. On the other hand, it is
well-known that many pharmaceutically relevant compounds are
capable of engaging multiple targets in vivo, giving rise to
polypharmacology. To explore and better understand promiscuous
binding characteristics of small molecules, we have searched X-ray
structures (and very few qualifying solution structures) for ligands
that bind to multiple distantly related or unrelated target proteins.
Experimental structures of a given ligand bound to different targets
represent high-confidence data for exploring promiscuous binding
events. A total of 192 ligands were identified that formed
crystallographic complexes with proteins from different families
and for which activity data were available. These “multifamily” compounds included endogenous ligands and were often more
polar than other bound compounds and active in the submicromolar range. Unexpectedly, many promiscuous ligands displayed
conserved or similar binding conformations in different active sites. Others were found to conformationally adjust to binding
sites of different architectures. A comprehensive analysis of ligand−target interactions revealed that multifamily ligands
frequently formed different interaction hotspots in binding sites, even if their bound conformations were similar, thus providing
a rationale for promiscuous binding events at the molecular level of detail. As a part of this work, all multifamily ligands we have
identified and associated activity data are made freely available.
1. INTRODUCTION
Compound optimization efforts in medicinal chemistry
traditionally aim to develop drug candidates that are highly
selective and potent toward a specific biological target. This
principle is based upon the assumption that therapeutic effects
following drug administration solely result from interactions
with a single target. However, this paradigm was called into
question and revised when it became evident that the efficacy
of drugs, but also side effects, frequently depended on
multitarget activities and associated functional consequences,
a concept referred to as “polypharmacology”.1−6
Despite the relevance of polypharmacology for drug efficacy,
compounds with promiscuous binding behavior are often
viewed controversially.7,8 This is the case because high hit rates
of small molecules in biological assays are frequently not the
result of multiple binding events.9 Rather, aggregation effects
and potential chemical reactivities under assay conditions can
lead to false positive assay signals.9−12 In light of concerns
about such artifacts, studying multitarget activities of ligands
and differentiating between false positive and true positive
interactions have become important tasks in medicinal
chemistry and biological screening.13−17
In addition to their relevance for drug development, the
study of promiscuous small molecules is also of high interest in
basic research. Importantly, physiological effects of endoge-
nous chemical entities such as coenzymes, substrates, or
transmitters are often elicited because of their ability to interact
with distantly related or unrelated proteins having diverse
functions.18,19 Hence, “true” promiscuity represents an evolu-
tionary principle for physiologically relevant ligands. However,
the molecular basis of promiscuous binding events remains to
be further explored.
Although the ligand specificity paradigm will continue to
play an important role in drug discovery, there are many
opportunities to utilize polypharmacology.3 For example,
multitarget compounds used for the treatment of a given
pathology might be repositioned for other therapeutic
applications that require engagement of different targets.20 A
text book example of such repurposing efforts is methotrexate,
a drug used for many years in cancer treatment, which has
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recently found alternative low-dose applications in the
treatment of inflammatory disorders like psoriasis and
rheumatoid arthritis.21 Notably, polypharmacology has high
potential for treatment of diseases that result from perturbation
of target networks and associated signaling pathways.
Promiscuous kinase inhibitors successfully used in oncology
are prime examples for compounds that interfere with target
networks and their signaling cascades.22
Given the complex nature of polypharmacology, rational
design of multitarget ligands is an equally challenging and
attractive area of research.3,7,23−25 To this end, several studies
have attempted to determine structure−activity relationship
profiles of multitarget compounds. For example, on the basis of
publicly available activity data, compounds with multitarget
activity were identified and similarity relationships between
them were explored.25−27 Furthermore, X-ray structures were
used to associate multitarget drugs with proteins having similar
functions,28 relate multitarget activities of ligands to protein
binding site similarity,29 or identify compounds bound to
targets from different families (multifamily ligands).30
Although structural data are limited, studying multitarget and
multifamily ligands on the basis of complex X-ray structures,
rather than assay data, has the intrinsic advantage that these
binding events are confirmed at the molecular level of detail
and can be investigated as such.
Herein, we have searched for multifamily ligands with
available X-ray [or nuclear magnetic resonance (NMR)]
structures to better understand origins of ligand promiscuity
across different target families. Therefore, we have carried out a
systematic search for experimental structures of small
molecules bound to multiple targets from different protein
families. A set of structure-based multifamily compounds was
identified that included endogenous ligands as well as
approved drugs. Molecular properties and bound conforma-
tions of these multifamily ligands were systematically analyzed
and interaction hotspots in different protein binding sites were
identified. Taken together, the results of our analysis shed light
on the ability of small molecules to interact with distantly or
unrelated targets.
2. RESULTS AND DISCUSSION
2.1. Identification and Characterization of Multi-
family Ligands. From 112 212 structures (entries) available
in the Protein Data Bank (PDB),31 26 073 bound ligands were
extracted. These ligands included 6496 organic compounds
with a molecular weight of at least 300 Da and one or more
reported activity values (in original references) of at least 10
μM (pIC50, pKi, or pKd ≥ 5). This set of PDB ligands provided
the basis of our study.
The preselected ligands were subjected to a two-stage
analysis. First, target family assignments were computationally
carried out in a consistent manner (without subjective
intervention) to identify ligands that were active against
different target families and ensure reproducibility of the
analysis (see Materials and Methods). Second, for each
designated multifamily ligand, assigned targets and binding
domains were carefully compared to examine similarities
between targets from different families and prioritize multi-
family ligands for promiscuity analysis, as further discussed
below.
Computational analysis of the preselected PDB ligands
identified 192 compounds that formed complexes with a
variety of target proteins from 2 to 16 different families. These
192 compounds were designated multifamily ligands and
further analyzed. Figure 1 shows exemplary compounds and
Figure 2 shows the distribution of multifamily ligands over
protein families. Kinases and other transferases formed the
largest number of complexes with multifamily ligands (with 42
and 36 ligands, respectively). The majority of complex
structures involved cytosolic enzymes, which are over-
represented in the PDB because of ease of crystallization.
Figure 1. Exemplary multifamily ligands. For each ligand, the PDB
Ligand Expo identifier (PDB-ID) is given and the number of
qualifying complex X-ray structures (entries), targets, and target
families is reported. Shown are exemplary ligands from (a) subset IV
and (b) subset III.
Figure 2. Distribution of multifamily ligands over target families. The
bar plot reports the distribution of multifamily ligands over families of
crystallographic targets according to the ChEMBL protein family
classification scheme.
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Multifamily ligands were available in complexes with 2 to
131 crystallographic targets, with a median value of 3 unique
targets per ligand. The 192 ligands were represented by a total
of 3398 complex structures. These structures only included 20
solution (NMR) structures of ligand−protein complexes and
34 NMR structures of ligand−DNA complexes (for complete-
ness, DNA was included as a biological target). The small
number of solution structures only entered the initial statistical
analysis of multifamily ligands. Subsequent analysis was
focused on X-ray structures. Distributions of potency (pIC50,
pKi, or pKd) values of the 192 multifamily ligands for X-ray
targets are shown in Figure 3. The distributions were broad
and interquartile ranges spanned several orders of magnitude,
with median values in the low micromolar to submicromolar
range.
In stage two of our analysis, targets of all multifamily ligands
were compared individually and the ligands were assigned to 4
different subsets:
Subset I: ligands whose multifamily assignment
depended on complexes with metabolizing enzymes or
serum proteins (10 ligands); II: endogenous ligands
(40); III: ligands binding to similar proteins from
different families or to similar binding domains (51);
and IV: multifamily ligands interacting with distinct
targets (91).
The 10 ligands from subset I were omitted from further
consideration because binding to serum proteins or metaboliz-
ing enzymes such as cytochromes is not relevant for
polypharmacology (for all remaining ligands, complexes with
such proteins were not included in subsequent analysis steps).
Endogenous ligands such as adenosine 5′-triphosphate (ATP)
or nucleoside derivatives have evolved to interact with different
proteins. As such, these naturally occurring ligands are set apart
from synthetic compounds and should best be separately
considered. Furthermore, proteins from different families
distinguished by established classification schemes might partly
be structurally related and have similar biological functions.
Therefore, subset III captured multifamily ligands for which at
least some of the participating proteins had similar enzymatic
functions or similar binding domains. By contrast, subset IV
contained ligands that interacted exclusively with unrelated or
distantly related targets (both in terms of structure and
function). Figure 1a shows representative examples of subset
IV ligands such as QUE that interacts with numerous distinct
targets. Figure 1b shows subset III ligands. For example, NGH
inhibits metalloproteases from 2 different families and BMF
binds to bromodomains in proteins from 4 different families.
On the basis of our analysis, the 91 multifamily ligands
belonged to subset IV having highest priority for promiscuity
analysis, given that they interacted with unrelated targets.
Therefore, specific examples discussed below were taken from
subset IV.
For the initial set of 192 multifamily ligands and all other
preselected PDB, different molecular properties were calcu-
lated and compared, revealing some interesting differences in
the topological polar surface area (TPSA) and S log P values.
Multifamily ligands had overall large TPSA (with a median of
145.5 Å) and low S log P values (median 1.7), indicating that
multifamily ligands were generally polar. The apparent increase
in hydrophilicity among multifamily ligands was further
investigated by calculating TPSA (Figure 4a) and S log P
values (Figure 4b) for individual ligand subsets. With a median
TPSA of 255.7 Å and S log P value of −2.2, endogenous
ligands were partlybut not exclusivelyresponsible for the
relative increase in hydrophilicity because they included a
variety of nucleosides with phosphate groups. However, even
after removal of all subset II ligands, the remaining multifamily
ligands had detectably higher hydrophilic character than other
PDB compounds, with a median TPSA of 120.5 Å vs. 101.7 Å
and median S log P value of 2.4 versus 3.4, respectively. Thus,
the multifamily activity of ligands was not attributable to
hydrophobic “stickiness”. Rather, they were more hydrophilic
in nature than many other PDB compounds, even when
endogenous ligands were excluded. Furthermore, only 17
multifamily ligands (<10%) were found to contain sub-
structures implicated in assay interference effects. We also
searched for structural analogues and analogue series among
Figure 3. Potency values. For multifamily ligands, the distributions of
different logarithmic potency values (pIC50, pKi, and pKd) are
reported in box plots. The yellow horizontal line indicates the median
value of each distribution (reported next to the line).
Figure 4. Molecular properties. The distributions of (a) TPSA and
(b) SlogP values for endogenous multifamily ligands (subset II, blue),
remaining multifamily ligands (white), and all preselected PDB
ligands (PDB CPDs, gray) are reported in box plots. The yellow
horizontal line indicates the median value of each distribution.
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multifamily ligands. Only a single series containing 3 analogues
was identified. Thus, multifamily ligands were not dominated
by individual compound classes but were structurally diverse.
2.2. Binding Conformations. Next, bound conformations
of each multifamily ligand were systematically superposed and
compared. Figure 5 shows exemplary pairwise superpositions
of target-dependent conformations. Figure 6 shows the
distribution of Root-Mean-Square Deviation (RMSD) values
resulting from exhaustive comparison of binding conforma-
tions of all 192 multifamily ligands. Pairwise rmsd values
ranged from close to 0 to 6.0 Å, with a median RMSD of 1.0 Å.
Thus, approximately half of the comparisons identified similar
binding conformations in different structural environments.
The third quartile reached a value of 1.8 Å. At this level,
conformations of typical ligands become dissimilar. Therefore,
approximately a quarter of the comparisons indicated target-
dependent conformational differences. However, overall most
bound conformations of multifamily ligands were similar,
regardless of the conformational space available to ligands and
differences in the geometry and shape of binding sites. Figure 6
also reports the corresponding distribution of RMSD values for
the 91 high-priority ligands from subset IV. In this case, the
median RMSD value was only 0.8 Å, thus even lower, despite
interactions with unrelated targets.
Hence, it remained to be determined how similar ligand
conformations were accommodated in different structural
environments.
2.3. Target−Ligand Interactions. Therefore, a systematic
analysis of intermolecular interactions was carried out (details
are provided in Materials and Methods). Directed polar
interactions including hydrogen bonds, ligand−metal contacts,
ionic, and π-interactions were accounted for and, in addition,
van der Waals (vdW) contacts between ligand atoms and
nonpolar amino acids. These vdW contacts were quantified as
an indicator of hydrophobic interactions and shape com-
plementarity. Figure 7 illustrates target−ligand interaction
analysis using indomethacin as an exemplary ligand bound to
human peroxisome proliferator-activated receptor γ
(PPARγ).32 Atoms involved in directed and/or vdW
interactions were uniquely indexed and individual atomic
contacts were counted. Then, contacts were mapped onto
ligand atoms and color-coded according to their frequency.
Figure 5. Binding conformations of a multifamily ligand. Shown are
exemplary pairwise superpositions of crystallographic conformations
of doxorubicin. As a reference conformation, doxorubicin bound to
DNA (Ligand Expo ID: DM2, PDB entry ID: 1DA9) is used (gray
carbon atoms) onto which bound conformations of doxorubicin
extracted from complex structures with diverse targets are superposed.
For each superposition, the RMSD value is reported.
Figure 6. Comparison of binding conformations. For all 192
multifamily ligands (MF PDB CPDs, blue) and the subset of
prioritized multifamily ligands (subset III, white), the distribution of
RMSD values for all pairwise superpositions of bound conformations
is reported in a box plot. The yellow horizontal line indicates the
median value of the distributions.
Figure 7. Identification of target−ligand interaction hotspots. For an
exemplary bound ligand (green carbon atoms, Ligand Expo ID: IMN,
PDB entry 3ADS), the atom-based number of directed interactions
(hydrogen bonds, ligand−metal contacts, ionic, and π-interactions)
and vdW interactions with hydrophobic protein residues are reported.
Atoms involved in interactions are indexed. In the X-ray structure,
directed interactions are shown as dotted lines and vdW contacts are
presented as magenta spheres. In the corresponding 2D representa-
tions, ligand atoms are color-coded according to the number of their
interactions (directed: light to dark green, vdW: light to dark orange).
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Accordingly, dark green and dark orange atoms, or groups of
atoms, indicated centers of polar and vdW interactions,
respectively, as illustrated in Figure 7. For each multifamily
ligand, interaction patterns were then monitored separately for
targets belonging to different families and compared. The
analysis revealed that multifamily ligands mostly formed
different “interaction hotspots” with targets belonging to
different families, even if bound conformations were similar,
as discussed in the following.
For the examples presented, binding site similarity between
participating protein families was also calculated (see Materials
and Methods) and binding sites reaching a threshold for
detectable similarity were identified.
2.4. Interaction Hotspots of Multifamily Ligands.
Interaction hotspots were defined as ligand atoms most
frequently involved in specific ligand−target interactions.
They were calculated by mapping detectable ligand−target
interactions on participating ligand atoms and determining
their frequency on a per-atom basis (see Materials and
Methods). Thus, so-defined hotspots revealed centers of
interactions in ligands and other regions that did not
participate in such interactions. Combining the analysis of
binding conformations and target−ligand interactions made it
possible to rationalize different multitarget binding events. For
example, indomethacin represents a well-characterized poly-
pharmacological drug33 that is known to interact with
unrelated targets including cyclooxygenases,34 phospholipase
A2,35 and PPARγ,32 and also serum albumin.36 As revealed by
its RMSD matrix in Figure 8a, indomethacin belongs to the
subset of multifamily ligands that display target-dependent
differences in binding conformations with largest RMSD values
exceeding 2.0 Å. Largest conformational variations were
observed for transcription factor binding compared to
hydrolases, reductases, and secreted proteins. Hence, indome-
thacin conformationally adapted to different structural environ-
ments. Figure 8b compares the interactions between
indomethacin and targets from different families. The aliphatic
carboxylic acid group of indomethacin was a conserved hotspot
for polar interactions across all 3 protein families. On the other
hand, aromatic interactions of the central indole ring moiety
were only observed in binding sites of reductases. However,
vdW interactions involving this moiety were mostly found in
reductases and the transcription factor. By contrast, in the
active site of hydrolases, no interactions with the central part of
indomethacin were detectable. Thus, binding of this drug
across different target families involved both conserved and
distinct interaction patterns, which was a recurrent theme
among multifamily ligands.
The HIV protease inhibitor ritonavir37 is an example of a
multifamily ligand with different binding conformations,
yielding largest RMSD values exceeding 3.0 Å (Figure 9a).
Among other targets, ritonavir is known to bind to cytochrome
P450 enzymes, which causes undesirable side effects and drug
interactions.38 The peptidomimetic nature of ritonavir with a
large number of rotatable bonds supports flexibility of binding
conformations. Accordingly, as shown in Figure 9b, this ligand
displayed different polar interaction patterns when bound to
proteases and hydrolases that were closely related and had
significant binding site similarity. Polar interactions in
proteases and hydrolases were centered on a hydroxyl group,
while distinct polar hotspots were identified for the thiazole
ring. Moreover, this ligand displayed overlapping yet distinct
vdW interactions in different binding sites with three hotspots,
Figure 8. Multifamily binding of indomethacin. (a) Shows an RMSD
value matrix for comparison of indomethacin conformations bound to
targets from different families. Each cell represents an RMSD value for
a pairwise superposition. Cells are color-coded according to RMSD
values (from light blue (0.0 Å) to purple (maximum rmsd). (b)
Shows interaction hotspots of indomethacin for different protein
families. The number of targets per family is given in parentheses. The
representation of interaction hotspots is according to Figure 7. A low
binding site similarity was detected for transcription factors, secreted
proteins, and hydrolases.
Figure 9. Multifamily binding of ritonavir. (a) RMSD matrix. (b)
Interaction hotspots for different protein families. The presentation is
according to Figure 8. A high binding site similarity was detected for
hydrolases and proteases.
ACS Omega Article
DOI: 10.1021/acsomega.8b03481
ACS Omega 2019, 4, 1729−1737
1733
only one of which (the central phenyl moiety) was shared by
the two target families. Hence, ritonavir provided an intuitive
example of a multifamily ligand where conformational
adaptability was accompanied by the formation of different
interaction hotspots.
Because ligand binding across different protein families was
not only attributable to conformational variability and resulting
differences in interaction hotspots, we reasoned that differ-
ences in interaction patterns should also be present for
multifamily ligands that bound with similar conformations to
different targets. For example, quercetin is a relatively small
and rigid compound that belongs to the large subset of
multifamily ligands with essentially conserved binding
conformations across different target families (with only one
exception), as illustrated by its RMSD matrix in Figure 10a.
Quercetin contains a polyphenolic flavonoid scaffold. Notably,
flavonoids were considered privileged substructures in drug
discovery39 capable of forming interactions with kinases,40
DNA,41 or hydrolases.42 In addition, there is crystallographic
evidence for the oxidative cleavage of quercetin by
quercetinase.43 However, polyphenols such as quercetin were
also implicated in reactivity under assay conditions and other
potential liabilities such as membrane perturbation, adding
them to the spectrum of interference compounds.12,13 X-ray
structures of quercetin in complex with DNA and targets from
three protein families also revealed both conserved and family-
dependent interaction hotspots, as shown in Figure 10b. The
3-hydroxy group of quercetin was consistently involved in
target−ligand interactions, whereas the carbonyl oxygen
formed a hydrolase-specific interaction hot spot. The C-ring
of quercetin was involved in π-interactions in all complexes
except when bound to hydrolases. Especially in kinases, all
three rings were involved in aromatic interactions. In addition,
extensive vdW contacts were formed when quercetin was
bound to reductases and kinases, which were largely absent in
hydrolases (and DNA).
Comparable conformational invariance was also observed for
the chemotherapeutic agent doxorubicin, given its rigid
structure. The presumed mechanism of action of doxorubicin
involves the intercalation of the planar anthracycline core with
the DNA double helix.44 Similar to quercetin, doxorubicin
contains structural elements that contribute to ligand−target
interactions but also cause assay liabilities and potentially
adverse pharmacological effects.45−47 In light of the complex
pharmacokinetics of anthracyclines, interactions of doxorubicin
with different target proteins were analyzed in a number of
crystallographic investigations including complexes with efflux
pumps48 and cytosolic reductases.49 Because of the rigidity of
the anthracycline core, limited conformational flexibility was
due to bond rotation in the terminal carboxylic acid and
aminoglycoside moiety, respectively (Figure 11a). Rather
unexpectedly, interaction analysis of doxorubicin revealed
that π-interactions of the aromatic core were only dominant
when binding to DNA but that vdW contacts involving this
moiety were preferentially observed in complexes with
reductases and a transporter (Figure 11b). By contrast, the
primary amine of the aminoglycoside was found to be a
conserved interaction hotspot across 3 protein families. On the
other hand, carbonyl and hydroxyl oxygens of the central
anthracycline core only formed polar contacts when binding to
reductases. Thus, polar and vdW interactions distinguished
binding of doxorubicin in different structural environments.
The ATP-competitive kinase inhibitor dinaciclib has much
more conformational freedom than quercetin and doxorubicin.
However, it also bound with similar conformations to cyclin-
dependent kinases50 and epigenetic regulators,51 as shown in
Figure 12a, with a maximum RMSD value of 1.6 Å. Cyclin-
dependent kinases and epigenetic regulators had detectable
Figure 10. Multifamily binding of quercetin. (a) RMSD matrix. (b)
Interaction hotspots for different protein families. No binding site
similarity was detected.
Figure 11. Multifamily binding of doxorubicin. (a) RMSD matrix. (b)
Interaction hotspots for different protein families. No binding site
similarity was detected.
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binding site similarity. Figure 12b compares interaction
hotspots of dinaciclib with these 2 protein families. In both
cases, extensive vdW interactions with essentially all parts of
the inhibitor were observed, reflecting a high degree of shape
complementarity in these binding sites. By contrast, distinct
hotspots for polar interactions emerged. For epigenetic
regulators, directed interactions with the central pyrazol[1,5-
a]pyrimidine scaffold were detected. On the other hand,
charge-assisted interactions and π-interactions involving the
pyridine-N-oxide moiety were prevalent in complexes with
kinases. Accordingly, dinaciclib was also representative of many
multifamily ligands that had largely conserved binding
conformations across different targets but formed different
interaction hotspots in changing protein environments.
3. CONCLUSIONS
In this work, we have systematically identified ligands with
available experimental structures of complexes with targets
from different families. These structures of multifamily ligands
provided firm evidence for the presence of true binding events.
Properties and binding characteristics of multifamily ligands
were analyzed in detail to better understand the molecular
basis of their promiscuous binding behavior. Multifamily
ligands also included drugs with known polypharmacology.
Surprisingly, multifamily ligands were overall slightly more
hydrophilic than other PDB compounds. Moreover, many
but not allmultifamily ligands had similar binding con-
formations when interacting with targets from different
families. In some instances, conformational variability in
different binding sites was expectedly accompanied by the
formation of different interaction hotspots. In other cases,
conserved binding conformations of rigid or flexible ligands
revealed overlapping yet distinct interaction hotspots across
different target families. The formation of target family-
dependent interaction hotspots in the presence of variable or
conserved binding conformations emerged as a recurrent
theme across multifamily ligands. The ligands interacted
similarly with targets from the same family, leading to family-
dependent hotspots, but interaction hotspots clearly differed
between families. These observations provided a rationale for
the promiscuous binding capacity of ligands at the molecular
level of detail.
4. MATERIALS AND METHODS
All calculations were carried out using in-house Python scripts
with the aid of RDKit52 and the OpenEye’s chemistry toolkit,53
KNIME protocols,54 and the molecular operating environment
(MOE).55
4.1. Ligands from X-ray Structures. X-ray structures and
associated compound data were extracted from the Ligand
Expo section56 of the PDB and complemented with
experimental binding affinity data from the PDBbind data-
base.57 Ligands were considered for further analysis if they had
a minimum molecular weight of 300 Da and if at least one
activity value of 10 μM (pIC50, pKi, or pKd) or better was
available. Application of the molecular weight and activity
cutoff ensured that salts, small organic components, and
molecular fragments were excluded. Molecular descriptors of
PDB ligands were calculated using RDKit. PDB ligands were
screened in silico for structures containing Pan Assay
Interference Compounds (PAINS)11 utilizing SMARTS58
strings obtained from three publicly available filters (ZINC,59
RDKit, and ChEMBL60).
4.2. Target Family Distribution. For crystallographic
targets, family assignments were obtained by matching
UniProt61 target identifiers to ChEMBL identifiers and
applying the ChEMBL protein family classification scheme.
In addition, the number of targets per compound was
determined on the basis of unique UniProt identifiers.
4.3. Searching for Structural Analogues. A systematic
search for analogues among multifamily ligands was carried out
using a matched molecular pair-based computational meth-
od.62
4.4. Analysis of Binding Conformations. For each
multifamily ligand, bound conformations were extracted from
the corresponding X-ray complexes and superposed. From
these superpositions, pairwise RMSD values of ligand
conformations were calculated using MOE.
4.5. Analysis of Target−Ligand Interactions. For
multifamily ligands, crystallographic target−ligand interactions
were systematically analyzed using a KNIME implementation
of MOE if two or more complexes representing a protein
family were available. Crystallographic water molecules were
removed from X-ray structures to avoid overestimation of
water contacts in complexes.63 Nonbonded interactions
involving ligand atoms were determined within a radius of
4.5 Å. Hydrogen bonds, ligand−metal contacts, ionic, and π-
interactions were identified with the aid an empirical geometry-
based scoring function.64 In addition, vdW contacts between
ligand atoms and hydrophobic protein residues were
determined by applying a maximal interaction energy of
−0.5 kcal/mol. The sum of all polar and vdW interactions was
calculated for each multifamily ligand atom over all binding
sites in X-ray structures of a given protein family. For each
family, the atom-based number of interactions was mapped
onto a 2D representation of the ligand64 using the chemistry
toolkit of RDKit. Atom positions were color-coded according
to the number of mapped interactions.
Figure 12. Multifamily binding of dinaciclib. (a) RMSD matrix. (b)
Interaction hotspots for different protein families. Binding site
similarity between epigenetic regulators and kinases was detected.
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4.6. Binding Site Similarity. Similarity of binding sites
from different protein families was analyzed using ProBiS.65
For pairwise comparison of nonredundant targets from
different families, the lowest recommended similarity z-score
of 1.0 was applied as a threshold for detectable binding site
similarity.65 If a pairwise comparison yielded a score of 1.0 or
greater, the binding sites were classified as similar.
4.7. Data Availability. All multifamily ligands, family
assignments, available affinity data, and the ligand subset
classification are made available as Table S1 of the Supporting
Information.
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Michael Gütschow: 0000-0002-9376-7897
Jürgen Bajorath: 0000-0002-0557-5714
Author Contributions
The study was carried out and the manuscript written with
contributions of all authors. All authors have approved the final
version of the manuscript.
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
The use of OpenEye’s toolkits was made possible by their free
academic licensing program.
■ REFERENCES
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Conclusions
This study completes the structure-based evaluation of compound promiscuity
provided in chapters 3 and 7. Molecular properties and binding modes of mul-
tifamily ligands were analyzed in detail to explore the molecular basis of their
promiscuous binding behavior.
Surprisingly, multifamily ligands polar, which was expcially the case for a
subset of endogenous ligands. Moreover, bound conformations of multifamily
ligands were overall similar, regardless of the conformational space available to
ligands and differences between binding sites in distantly related or unrelated
targets. In some cases, when conformational variability in different binding site oc-
curred, it was also accompanied by the formation of different interaction hotspots.
Across multifamily ligands, the formation of such family dependent interaction
hotspots emerged as a recurrent theme. These observations rationalized the capac-
ity of promiscuous ligands to bind multiple targets from different families at the
molecular level of detail.
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Conclusion
Biological screening data carry the inherent risk of being compromised by arti-
ficial readouts resulting from numerous assay interference mechanisms. Therefore,
it is a major concern in biological screening, medicinal chemistry, and chemoin-
formatics to provide confirmatory evidence for the biological activity of hit com-
pounds. This evidence is needed to promote candidates for hit-to-lead optimiza-
tion or to identify truly promiscuous compounds that can be used in polypharma-
cology efforts. In this thesis, chemoinformatic methods are utilized to elucidate
the PAINS actions and provide a reference frame for judging assay interference in
medicinal chemistry. Additionally, on the basis of structurally confirmed binding
events, promiscuity is studied at the molecular level of detail.
The first representative study (chapter 2) provided initial insight into the un-
certainties associated with biological screening data. Of 466 extensively tested
promiscuous screening compounds, more than half were identified as PAINS or
aggregators. In addition, visual inspection of the remaining molecules revealed
that only a subset of 30 compounds were not associated with evident chemical
liabilities. This indicated that substructure filters did not comprehensively cover
interference mechanisms and had intrinsic limitations. For example, the study
demonstrated that specific PAINS SMARTS patterns did not take tautomerism into
account. It was shown that a confined number of truly promiscuous compounds
that qualify for polypharmacology existed. However, the identification of such
compounds required careful analysis of biological screening data beyond the sole
use of structural filters. In chapter 3, X-ray structures of target-ligand complexes
containing PAINS were identified and explored. An unexpectedly high number
of 1107 unique ligands that contained a PAINS motif was present in 2874 X-ray
complexes. By considering structurally confirmed binding events, these findings
added a new dimension to the challenging assessment of assay interference activi-
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ties. For example, for notorious PAINS such as catechols and aminoacridines, the
presence of specific ligand-target interactions and reactivity under assay condi-
tions were not mutually exclusive. Notably, complexes were identified in which
distinct structural modifications prevented interference reactions to take place.
This was considered a particulary interesting finding because the structural en-
vironment in which a PAINS substructure was presented determined its activity.
Expanding the hypothesis of structural context dependence, ASs of extensively
tested screening compounds containing PAINS were identifed and analyzed in
chapter 4. In this study, the systematic assessment of assay hit rates revealed vary-
ing activity profiles among 177 individual PAINS classes present in the ASs. Thus,
distinct PAINS motifs, such as catechols or quinones, were predominantly found
in series with high rates, while others often displayed low activity or inactivity,
including aniline-derivatives. Additionally, the ASs enabled a SAR analysis of
interference activities. For example, structural modifications of rhodanines and
Mannich bases were identified that had a significant influence on hit rates of
these PAINS. These studies provided a novel reference frame for the knowledge-
based assessment of assay interference. Subsequently, machine-learning models
were introduced in chapter 5 to enable a systematic classification between highly
promiscuous and consistently inactive PAINS, thus bypassing challenges of case-
by-case analysis by medicinal chemists. Classification models were successfully
applied to balanced sets of PAINS represented by structural fingerprints. ECFP4
features that favored successful predictions of SVM models were identified and
mapped onto correctly classified PAINS. This allowed addressing the ‘black-box’
character of machine learning models and rationalize the classification process,
thereby revealing novel insights into the structural context dependency of PAINS.
For example, electron withdrawing substituents in the vicinity of electrophilic
Michael acceptors favored the correct classification by SVM models. In chapter 6
the SAR analysis of interference compounds was complemented by the provision
of MMSs containing compounds with high assay promiscuity. These series were
not submitted to filtering steps, thereby circumventing previously discussed short-
comings of substructure alerts. Hence, they can be utilized for an unrestricted
systematic assessment of assay interference taking structural context information
into account.
In chapter 7, structure-based confirmatory evidence for true binding events
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was revisited and expanded. In this study, 702 crystallographic multifamily lig-
ands were identified that bound to multiple distantly related or unrelated crys-
tallographic targets. Of these, 355 multifamily ligands were also present in the
medicinal chemistry literature and were generally promiscuous. The availability
of these ligands in complex with multiple targets lend credence to their promis-
cuous nature. Therefore, 133 ASB scaffolds were isolated from series containing
multifamily ligands and their analogs from medicinal chemistry, hence provid-
ing reference templates for multitarget and polypharmacological ligand design.
In chapter 8, properties and binding characteristics of multifamily ligands were
analyzed in detail to understand the molecular basis of their promiscuous binding
behavior. Multifamily ligands included drugs with known pharmacology such
as indomethacin and were overall more hydrophilic than other PDB compounds.
Many, but not all, multifamily ligands adopted similar binding conformations
when interacting with distinct targets. Notably, after systematic assessment of
target-ligand interactions, family dependent interaction hotspots were identified.
Typically, ligands interacted similarly with targets from the same family, but
formed different interaction hotspots in binding sites of targets from another
family.
In conclusion, this thesis introduced and explored the structural context depen-
dence of interference mechanisms, thereby providing a reference frame for the con-
firmation of compound integrity in medicinal chemistry. It has also distinguished
promiscuity from artificial mutiltarget activity and utilized three-dimensional
target structures to provide a rationale for promiscuous binding at the molecular
level of detail.
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